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Abstract
Progress in the diagnostics and therapy of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NEN), results of new randomised 
clinical trials, and publication of the new guidelines by the European Neuroendocrine Tumour Society (ENETS) have led the Polish Net-
work of Neuroendocrine Tumours to update its 2013 guidelines regarding on management of these neoplasms.
This article presents the general recommendations for the management of NENs, developed by experts during the 3rd Round Table 
Conference — Diagnosis and therapy of gastro-entero-pancreatic neuroendocrine neoplasms: Polish recommendations in view of current European 
recommendations, which took place in December 2016 in Żelechów near Warsaw. Based on the extensive experience of the centres dealing 
with this type of neoplasms we believe that we have developed the optimal management system, for these patients which applies the 
most recent achievements and can be implemented effectively in Poland.
These management guidelines have been arranged in the following order:
gastric and duodenal NENs (including gastrinoma); pancreatic NENs; NENs of the small intestine and appendix, and colorectal NENs.
(Endokrynol Pol 2017; 68 (2): 79–110)
Key words: gastro-entero-pancreatic neuroendocrine neoplasms; diagnosis; therapy
1. Epidemiology
Gastro-entero-pancreatic neuroendocrine neoplasms/ 
/tumours (GEP NENs/NETs) develope from the diffuse 
endocrine system (DES) cells present in the gastroin-
testinal tract and in the pancreas. The detection rate for 
neuroendocrine neoplasms (NENs) has increased re-
cently [1, 2]. Between 1973 and 2004, the incidence rates 
of NENs increased from 2.1 to 5.25 new cases/100,000 
people/year, with the most frequently reported primary 
tumour site being the small intestine (37.4%). Since the 
year 2000, rectal NENs are detected more frequently 
than small intestinal NENs [1–4].
The prevalence of NENs in the years 1994-2009 
increased from 2.48 to 5.86 per 100,000 / year [4].
Following epidemiological studies conducted in the 
USA (SEER: Surveillance Epidemiology End Results) 
and Norway (NRC: Norwegian Registry of Cancer), an 
increase in the incidence of gastric and rectal NENs has 
been observed, as well as lower incidence of NENs of 
the appendix [3]. Currently, the mean general preva-
lence rate for these neoplasms is 35 cases in 100,000. 
A slight dominance of male patients (5.35/100,000/year) 
has been observed, compared to females (4.76/100,000/ 
/year) [1, 3, 5]. Approximately 70% of neuroendocrine 
tumours are GEP NENs, which account for approx. 
2% of all gastrointestinal neoplasms [1, 4] and consti-
tute a rare, heterogeneous group of neoplasms [6, 7]. 
If these neoplasms demonstrate hormonal activity 
they are called functional tumours. Those that do not 
produce hormones and/or biogenic amines in quanti-
ties sufficient to present clinical symptoms are called 
non-functional tumours. Over 50% of GEP NENs are 
neoplasms, which are most frequently found acciden-
tally, during a surgical procedure, in the small intestine 
and in the appendix, as well as in the diagnosis of 
distant metastases, mostly to the liver [1].
The incidence rate of NENs, both functional and 
non-functional, derived from different parts of the 
gastrointestinal tract and the pancreas are discussed 
in other sections of this document.
2. Diagnostics
2.1. Biochemical diagnostics
In the biochemical diagnostics of NENs the following 
should be considered:
A. Non-specific markers
Determination of serum (or, less often, plasma) chromogra-
nin A (CgA) concentration is the most commonly used 
test [1, 8, 9]. In the blood, CgA is a relatively stable protein. 
However, there are different methods of determining CgA 
concentration: radioimmunological (RIA) or enzymatic 
(ELISA) methods using blood serum or plasma [10]. Un-
fortunately, there are no international CgA standards, and 
the differences between available tests are significant. To 
monitor the course of the disease, it is recommended to de-
termine the CgA concentration using the same method [1]. 
ENETS experts emphasise in recent guidelines that CgA 
may be useful for the diagnosis, assessment of response 
to treatment, and detection of disease progress or early 
stage recurrence. However, they indicate an urgent need 
to standardise the determination of CgA [4].
The CgA assay is useful in:
 — Diagnosing NEN CgA levels are raised in most 
gastrointestinal and respiratory NENs, particularly 
in the generalisation phase, but results within refe-
rence range do not exclude the diagnosis of NET. 
The sensitivity of the CgA concentration test varies 
in different neoplasms, ranging from 10% to 100%, 
while its specificity is 68 to 100%. The highest sen-
sitivities have been observed in gastrinoma, gluca-
gonoma, and small intestinal NETs. Particularly high 
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CgA concentrations are found in NENs of the small 
intestine, with hepatic metastases and symptoms of 
carcinoid syndrome, where the CgA concentration 
may be up to an order of magnitude higher than 
normal. On the other hand, in benign insulinomas 
CgA concentrations are often within the reference 
range. In neuroendocrine carcinomas (NECs), CgA 
concentrations are often lower than in well-dif-
ferentiated NETs. Concentrations exceeding the 
reference values are not always caused by a NEN, 
therefore they are not tantamount to diagnosis 
[1, 11, 12]. Therefore, while interpreting CgA results, 
it is necessary to know which test has been used and 
whether possible causes for false positive or false 
negative results arise (Table I) [1].
 — As a prognostic factor for survival and a marker for 
monitoring the course of the disease, and of GEP 
NEN treatment. CgA concentrations are independ-
ent prognostic factors for survival in patients with 
small intestinal and pancreatic NENs [1, 13]. Use 
of somatostatin analogues (SSA) considerably low-
ers CgA concentrations, in the case of progressing 
disease. Increased CgA concentration during treat-
ment with somatostatin analogues may reflect lack 
of control of the tumour secretory function and/or 
its growth. Early decrease in CgA concentration in 
patients with pancreatic NETs during treatment with 
everolimus is also a favourable prognostic factor for 
progression-free survival [1, 13].
Another non-specific NEN marker is neuron-specific 
enolase (NSE). NSE has lower sensitivity and specifi-
city (30–50%) in diagnosing GEP NENs, compared to 
CgA. Increased NSE concentration may be associated 
with poorly differentiated NECs. The specificity of this 
marker is 63% in LCNEC (large cell NEC) and 62% in 
SCNEC (small cell NEC). NSE is also an independent 
prognostic factor for NECs. Its sensitivity in NET G1 and 
G2 is significantly lower: 19% and 54%, respectively. 
Simultaneous CgA and NSE determination is more 
sensitive and specific in the diagnosis of NENs [13, 14].
Pancreatic polypeptide (PP) may be a useful marker 
for non-functional pancreatic NENs, especially those 
associated with MEN1 syndrome [9].
Chromogranin B (CgB) is also mentioned as a non-
specific marker as its concentration may be increased 
in insulinoma, rectal NETs and NETs of the ovaries. 
Pancreostatin is a fragment of CgA, and it has been 
suggested that proton pump inhibitors (PPIs) do not 
affect pancreostatin concentration. The availability of 
these tests in Poland is limited [1, 9].
Highly promising are new molecular markers, espe-
cially the NETest, which analyses the expression profiles 
of selected gene transcripts, specific for NENs. Perform-
ing this test is justified at the stage of NEN diagnosis, as 
well as for monitoring the course of the disease, response 
to treatment, and early detection of progression [15–17].
Circulating microRNAs are promising biomarkers of 
NENs, due to their presence and stability in the body 
fluids, and their specificity for particular neoplasms [18].
B. Specific markers
The choice of specific GEP NEN markers depends on 
the clinical manifestation and type of neoplasm sus-
pected (Table II) [6, 12, 19, 20]. Direct measurement of 
the concentrations of specific peptides, biogenic amines, 
and hormones produced by NET cells is useful not only 
in diagnosing, but also in monitoring the treatment [12]. 
Details of biochemical diagnostics in individual clini-
cal syndromes are discussed in other sections of this 
recommendation.
The most frequently observed set of clinical symp-
toms associated with hormonal activity of NEN is the 
carcinoid syndrome. The clinical picture is discussed 
in the section on NENs of the small intestine and the 
appendix (see p. 223–236). The classical form depends 
mainly on excessive serotonin secretion. An atypical 
form is observed in pulmonary carcinoid tumours 
and in gastric NENs; it depends on excessive secretion 
of serotonin, 5-hydroxytryptophan (5-HT; serotonin 
precursor), and/or histamine.
Serotonin is produced by 70% of NETs, mostly 
arising in the small intestine, including the ileum, the 
proximal large intestine, and the appendix, and by 
Table I. Reasons other than GEP-NEN, for elevated serum 
CgA concentration [1]
Reasons other than GEP NEN for increased serum CgA concentration
Receiving proton pump inhibitors and histamine H2-receptor 
blockers (if possible, they should be discontinued at least 7–14 days 
before the test) 
Atrophic gastritis
Renal failure
Meal or physical effort 2–4 hours before the blood draw
Other neoplasms: prostate cancer, small cell lung carcinoma, 
medullary thyroid cancer, pheochromocytoma, hepatic cancer, 
pancreatic adenocarcinoma
Other non-neoplastic causes of increased CgA concentration (usually 
with a lesser effect on CgA levels):
— chronic inflammations, including rheumatoid arthritis (presence  
of IgM rheumatoid factor), COPD
— gastrointestinal diseases, including inflammatory bowel disease, 
hepatitis, cirrhosis, and pancreatitis
— cardio-vascular diseases, including cardiac failure, myocardial 
infarction
— endocrine diseases, including hyperthyroidism or 
hyperparathyroidism, treatment with glucocorticoids
— others, e.g. Parkinson’s disease
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10–35% of gastric and pulmonary NENs. The screen-
ing test for carcinoid syndrome includes two assays 
of daily urinary excretion of a serotonin metabolite: 
5-hydroxyindoleacetic acid (5-HIAA), provided that 
a proper diet has been followed. It is also important 
to acidify urine during sample collection (Table III) 
[1, 11, 12, 21]. The reference range is 2–8 mg/day (10– 
–42 mmol/d). Possible false-positives and false nega-
tives are presented in Table III [1, 11, 12, 21].
Gastro-entero-pancreatic NENs (mostly of the pan-
creas) may cause ectopic production of: ACTH (caus-
ing ACTH-dependent Cushing’s syndrome), GHRH 
(causing acromegaly), vasopressin (causing SIADH), 
and PTH-rP (causing hypercalcaemia). The diagnostics 
of these syndromes depends on clinical symptoms [1].
In all patients with foregut NENs, particularly in 
patients with NENs of the thymus, duodenum (gastrino-
ma), and pancreas, examinations for multiple endocrine 
neoplasia type 1 (MEN1) should be performed [22]. Basic 
screening tests in MEN1 include concentrations of ion-
ized or total calcium, parathyroid hormone (intact PTH), 
gastrin, prolactin, and IGF-1. In patients with suspected 
MEN1, molecular tests should be considered to detect 
mutation in the MEN1 menin-coding gene [1, 23].
Minimal consensus statement on biochemical exam-
inations:
 — In patients with suspected NEN, CgA concentration 
should be determined (*evidence level 3).
 — In patients diagnosed with NEN in the dissemination 
phase, CgA concentration should be determined (*evi-
dence level 3) — also concentrations of hormones and 
substances specific for a given syndrome, depending on 
the clinical symptoms presented by the patient.
 — If MEN1 is suspected, it is recommended that the concen-
tration of ionized calcium, parathyroid hormone (PTH), 
and pituitary hormones (mainly prolactin) are deter-
mined, and conducting genetic tests should be considered 
(*evidence level 3).
Details of biochemical diagnostics are discussed in other 
sections of this recommendation.
The proposed algorithm of diagnostic and therapeutic 
management is presented in Figure 1 [1].
2.2. Pathomorphological diagnostics
2.2.1. Histopathological classification of NENs
Following the recommendations of the European 
Neuroendocrine Tumour Society (ENETS), since 2000 
neuroendocrine neoplasms/tumours (NENs/NETs) have 
been diagnosed on the basis of the type of cell and site 
organ, histological type, including their differentiation 
and histological maturity grading (G), and pathomor-
phological advancement (pTNM), as well as clinical 
advancement staging (S) [1]. In 2006, Rindi proposed 
an organ-based assessment of the pathological advance-
ment of NENs, pTNM/ENETS [24]. However, according 
to ENETS, the most important histopathological char-
acteristic of clinical significance is the grade (G) of the 
neoplasm’s histological differentiation, assessed based on 
the Ki-67 proliferative index and the number of mitotic 
figures. The histopathological grade (G) is the key micro-
scopic feature with a prognostic and predictive value in 
the treatment of patients with gastrointestinal NENs. It 
is an independent parameter dividing NENs into three 
groups, according to the predicted clinical behaviour 
Table III. Causes of false-positive and false-negative 
assessments of daily urinary 5-HIAA excretion [1, 11, 12, 21]
False-positives False-negatives
Food products rich in tryptophan: 
avocado, bananas, kiwi, pineapples, 
walnuts, plums, aubergine, and 
cheese.
Discontinue 3 days before the 
collection
Food products: ethanol
Medicines: paracetamol, 
phenobarbital, ephedrine, and 
certain cytostatics (Cisplatin, 
5-fluorouracil)
Discontinue 3 days before the 
collection
Medicines: neuroleptics, 
MAO inhibitors, methyldopa, 
isoniazid, acetylsalicylic 
acid, heparin, and tricyclic 
antidepressants
Discontinue 3 days before the 
collection
Renal failure
Abnormal urine acidification!
During the sample collection, 
add 10 ml of 25% HCL to urine, 
to reduce the pH to 1.5–4.0.
Incorrectly collected daily 
urine sample
(determination of daily 
creatinine excretion, plastic 
containers, stored in a fridge)
Table II. Selected biochemical markers in GEP NEN 
diagnostics [1, 6, 12, 19, 20]
Primary NEN site Biochemical markers
Stomach – type I, II Gastrin
Duodenum Gastrin
Duodenum, pancreas SST (somatostatin)
Small intestine, ileum, 
proximal large intestine
5HIAA
Pancreas glucose, insulin, peptide C
Gastrin
Glucagon
VIP
*evidence level according to OCEBM [274]
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Figure 2. Principles of treating liver NET metastases [modified after refs. to 1, 160, 161]
Figure 1. Proposed GEP NEN management algorithm [1]
of the disease: lesions of low (G1), moderate (G2), and 
high (G3) malignancy. The criteria for the assessment of 
the G feature defined by ENETS in 2006 [24] were sub-
sequently adopted by the WHO, which resulted in the 
ENETS/WHO 2010 integrated system for the assessment 
of histological grading of NENs. Table IV [25] presents 
two methods for assessing the histological malignancy 
grading of NENs, based on two criteria. The first is the 
*evidence level according to OCEBM [274]
84
Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms Kos-Kudła Beata et al.
SZ
K
O
LE
N
IE
 
PO
D
YP
LO
M
O
W
E
number of mitotic figures, counted in ten high-power 
fields with a magnification of 40 × (1 HPF = 2 mm2). 
It is recommended to examine 50 high-power fields and 
select 10 fields of the highest mitotic activity (hot spots). 
The other criterion is the assessment of the Ki-67 pro-
liferation index, determined by immunohistochemical 
analysis of the MIB1 antigen expression. It is expressed as 
the percentage of cells with MIB1 immunohistochemical 
expression in the highest activity fields, calculated in 500 
to 2000 tumour cells. Where the assessment by these two 
methods provides different grades for the tumour, the 
Ki-67 proliferation index usually provides a higher value, 
and it should be accepted as the recommended grade. 
The above-mentioned division of NENs into two groups 
is the basis for the classification systems and therapeutic 
choices for this group of neoplasms [26, 27, 28].
The WHO 2010 classification system, based on the 
differentiation and histological maturity grade (G), in-
troduced the division of gastro-entero-pancreatic NENs 
into two basic categories, different in terms of clinical 
behaviour and treatment [25]. The first group comprises 
well-differentiated neoplasms, morphologically corre-
sponding to those referred to as carcinoids before 2000, 
and with a proliferation index of ≤ 20% — NET G1 and 
NET G2 (well-differentiated neuroendocrine tumours, 
G1 and G2). They are made up of cells resembling nor-
mal neuroendocrine cells, forming a trabecular, rosette 
nest, or pseudoglandular structures and expressing 
neuroendocrine markers in the cytoplasm, usually 
demonstrating extensive synaptophysin, CgA, and hor-
monal expression, dependent on the tumour location, 
and a small or medium nuclear atypia, below 20 mitotic 
figures / 10 HPF. Tumours in this category are classified 
and treated according to criteria applicable to well-
differentiated neuroendocrine neoplasms, NETs [29, 30]. 
The other group were neuroendocrine neoplasms, with 
a Ki-67 proliferation index above 20%, in the WHO 2010 
classification system referred to as neuroendocrine 
carcinomas (NECs). According to the 2017 American 
Joint Committee on Cancer (AJCC/UICC) 8th Edition, the 
group of poorly differentiated G3 neuroendocrine neo-
plasms (NECs) is heterogeneous. Within this group, in 
each organ of the gastrointestinal system a small group 
of well-differentiated neoplasms was distinguished, 
with Ki-67 above 20%, usually from 21% to 50% (well 
differentiated G3 NETs) [31–37]. Contrary to NET G3, 
the remaining poorly differentiated neuroendocrine 
neoplasms with Ki-67 above 20%, typically of over 50%, 
were high-grade neuroendocrine carcinomas (NECs), 
divided into large and small cell carcinomas. Their 
course is particularly aggressive, resembling lung can-
cers of similar morphology. They are composed of small 
or large cells, only occasionally creating structures that 
resemble those of neuroendocrine tumours. NECs usu-
ally demonstrate an intense and extensive expression 
of synaptophysin, with a weaker expression of CgA, 
marked nuclear atypia, necrosis, and over 20 mitotic 
figures/10 HPF. Information about the heterogeneity 
of poorly differentiated neuroendocrine neoplasms 
with a proliferation index above 20% is presented in 
various publications [38–41]. In a study published in 
2017, Italian authors from Milan demonstrated a cor-
relation between overall survival (OS) and the NEC 
group. According to their studies, the OS for NET G3 
was 43.6 months, for NECs with a proliferation index 
Ki-67 between 20% and 55% the OS was 24.5 months, 
and for NECs with Ki-67 equal to or higher than 55% it 
was 5.3 months [42]. A proposed new classification of 
NENs, including groups in the NEC category accord-
ing to 2017 AJCC/UICC, is presented in Table V [31–36].
The next group consists of neoplasms characterised 
by a complex exocrine and endocrine structure (mixed 
adenoendocrine carcinoma), and at least a 30% content 
of a given component determines its diagnosis. The 
diagnosis of this type of neoplasm is confirmed by 
immunohistochemical examinations with the use of 
particular antibodies [37, 43–46].
High-grade neuroendocrine carcinomas (NECs), 
goblet-cell carcinoids, and other mixed glandular-neu-
roendocrine cancers are classified following the criteria 
for classical glandular cancers typical for a given organ 
of the gastrointestinal tract.
2.2.2. Obligatory and conditional methods  
of pathomorphological examination in NENs
ENETS guidelines present rules for examinations of the 
material, depending on its type. Fine-needle aspiration 
biopsy is not recommended as a diagnostic method in 
the case of non-diagnosed primary tumour. It may be 
used to confirm the presence of metastases from the 
established point of origin [24, 47, 48].
Table IV. Grading criteria for assessment malignancy of 
neuroendocrine tumours [34, 35, 37]
Histological malignancy 
grade of NEN 
(G)
Mitotic activity/no. 
of mitotic figures 
/10 HPF
Ki-67 proliferation 
index/% of cells 
(per 2,000 cells)
G1 — well differentiated 
of low malignancy
< 2 < 3
G2 — moderately 
differentiated,
of medium malignancy
2–20 3–20
G3 — poorly 
differentiated, of high 
malignancy
> 20 > 20
*evidence level according to OCEBM [274]
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The principles of preparation of the biopsy material 
from the primary tumour or from metastases, and of 
the surgical material, are presented in Table VI and VII.
Minimal consensus statement on pathomorphological 
examination:
1. In the pathomorphological diagnostics of a small biopsy 
(excision from the lesion), it is recommended to diagnose 
the type of neoplasm, well-differentiated — NET, or poorly 
differentiated — NEC, neuroendocrine neoplasm/tumour 
— MINEN (mixed neuroendocrine non-neuroendocrine 
neoplasms), and the grade (G1, G2, G3 in NETs). How-
ever, the quantity of biopsy material may be insufficient 
and not representative of the entire tumour. TNM staging 
of the neoplasm is also recommended in the diagnostics 
of surgical material and polyps with the morphology of 
NENs, or a biopsy from the liver, with an established 
original tumour site, or to complete the data from imag-
ing examinations. The assessment of resection margins 
of a polyp with the morphology of a NET following its 
endoscopic excision (obligatory in the case of colonic NET), 
or surgical margins in the surgical material, is clinically 
useful. Pathomorphological diagnosis of a NEN should al-
ways be confirmed by immunohistochemical examination, 
including the assessment of expression of chromogranin 
A, synaptophysin, and the Ki-67 proliferation activity 
with the MIB1 antibody.
Table V. Proposed NEN classification incorporating the heterogeneous NEC group, according to AJCC [31–37]
NEUROENDOCRINE NEOPLASMS, NEN
NEN with proliferation index below 20% NEN with proliferation index above 20%
NET G1 NET G2 NET G3 NEC
Well-differentiated tumours Neuroendocrine cancers
Well-differentiated tumours with Ki-67 proliferation  
index below 3%
Well-differentiated tumours 
with Ki-67 proliferation index 
from 3% to 20%
Well-differentiated 
tumours with Ki-67 
proliferation index above 
20%, usually between 21 
and 55%
Neuroendocrine cancers 
with proliferation index 
above 21%, usually  
above 55% 
— large-cell cancers 
— small-cell cancers
Table VII. Principles of macroscopic examination of surgically 
obtained NEN tissues [24, 46, 47]
Principles of macroscopic examination of surgical NEN material
Obligatory:
— determination of: location, number of tumours, size (three 
dimensions)
— assessment of tumour cross-section appearance: solid/cystic, 
necrosis present
— assessment of tissues surrounding the tumour / invasion of 
adjacent organs
— marking surgical margins with ink
— excision of lymph nodes
Conditional:
— obtaining and preserving a fresh fragment of the tumour for 
scientific research
Immunohistochemical examination
Obligatory:
— Immunohistochemical assessment of neuroendocrine markers: 
synaptophysin, chromogranin A
— immunohistochemical assessment of Ki-67/MIB1 proliferative activity
Conditional:
Immunohistochemical examination of hormonal expression (insulin, gastrin, 
serotonin, etc.) if symptoms of tumour hormonal activity occur:
— assessment of metastases of functional tumours to the liver or 
lymph nodes if the original tumour site is unknown
— confirmation of the clinical symptoms of functional tumours
— immunohistochemical assessment of somatostatin receptors (e.g. 
SSTR2) for therapeutic purposes
— immunohistochemical assessment of vascular markers expression 
to examine angioinvasion
Table VI. Principles of cytological and histopathological 
examination of tissue specimens in neuroendocrine neoplasms 
[24, 46, 47]
Type of material tested Recommendations, assessment 
methods
FNA — fine needle aspiration In metastases with an established 
primary tumour site
Biopsy from the primary 
tumour or from metastases 
(liver, lymph nodes)
Tissue material preserved in formalin
The preparation directly undergoes 
the process of technical preparation 
(without macroscopic assessment)
Surgical material Conditional:
Recommended freezing of the 
tumour sample before preservation 
in formalin
Obligatory:
Tissue specimen preserved in 
formalin, examined macroscopically, 
undergoes the process of technical 
preparation for microscopic 
preparations
*evidence level according to OCEBM [274]
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2. The minimum histopathological report for the NEN surgi-
cal material should include:
 — clinical data: anatomical location of the tumour, clini-
cal symptoms in the case of functional neoplasms, and 
the name of the endoscopic or surgical procedure;
 — macroscopic features: tumour description, including 
its location, cross-sectional appearance, relation to the 
surrounding tissue and surgical margins, according 
to the guidelines for the organ;
 — microscopic features: description of the histoforma-
tive tumour structures and determination of the cell 
type, determination of the Ki-67/MIB1 proliferation 
index, and of the mitotic index according to the 
ENETS/WHO system (G1-G3), studied in the regions 
of the highest activity (hot-spot), and determination 
of histological maturity (G feature);
 — description of histopathological parameters of tumour 
invasion: angiolymphatic invasion, nerve infiltration, 
presence of necrosis, invasion of the tumour capsule 
(pseudo-capsule), and determination of the depth of infil-
tration into the organ wall or adjacent tissue and organs;
 — determination of immunohistochemical expression: 
obligatory CgA, synaptophysin, and Ki-67 with MIB1 
antibodies, and conditionally, as ordered by clinicians, 
other hormonal markers;
 — description of the tumour metastases, if present;
 — description of surgical margins;
 — description of other parameters, if present, such as 
inflammation, or another neoplastic component.
3. Diagnosis (pathomorphological diagnosis)
The histopathological report should end with a diagnosis 
containing the following parameters:
 — type of neoplasm according to the WHO classification 
(obligatory);
 — histological grade (G) according to the ENETS/WHO 
2017 guidelines, updated by 2017 AJCC Cancer Stag-
ing 8th edition (obligatory);
 — pTNM pathological staging according to the ENET 
and/or TNM AJCC/UICC criteria, with the year of 
edition (obligatory);
 — polypectomy margins or surgical margins;
 — assessment of the dominant cell type (conditional);
 — preoperative secretion levels of insulin, gastrin, and 
serotonin (if secreted);
 — suggested original tumour site in the case of hepatic 
tumours or metastases to the lymph nodes with un-
known original NEN location (*evidence level 3).
2.3. Diagnostic imaging
Diagnostic imaging of NENs is difficult due to their 
small size, often atypical location, and non-specific clini-
cal symptoms. Therefore, it is necessary to use different 
imaging methods, both anatomical and functional.
The anatomical imaging methods include:
 — ultrasonography (USG), especially endoscopic ul-
trasonography (EUS),
 — computed tomography (CT),
 — magnetic resonance imaging (MRI),
 — endoscopy,
 — capsule endoscopy.
Classical imaging methods (i.e. CT, USG, MRI) are use-
ful primarily in the assessment of the stage of the disease, 
and monitoring of the response to treatment. They also 
play an important role in planning the surgical manage-
ment of the primary tumour. Moreover, they enable the 
performing of a fine-needle or large-needle biopsy.
Over the last few years, endoscopic techniques have 
developed significantly. Their accessibility has also in-
creased. Today, these methods enable the conducting 
of both diagnostic and therapeutic procedures.
An important achievement in the diagnostics of 
NENs was the introduction of scintigraphic examina-
tions demonstrating the expression of somatostatin 
receptors (SRI, somatostatin receptor imaging). These 
are functional tests, which enable the characterisation 
of lesions on the molecular level [49, 50].
In Poland, 111In-labelled somatostatin analogues are 
no longer used in the diagnostics of NENs. In clinical 
practice, commonly used are 99mTc-labelled agonists 
of somatostatin receptors: 99mTc-HYNIC-TATE and 
99mTc-EDDA/HYNIC-TOC, both characterised by a simi-
lar sensitivity in the imaging of NENs [51].
Tests using these methods demonstrate a higher 
sensitivity in the diagnosis of primary tumours, as well 
as of osseous and pulmonary metastases.
Combined use of morphological and functional 
imaging techniques has improved the sensitivity and 
specificity of diagnostic methods in NENs [52–55].
Morphological and functional examinations are 
used in:
 — assessment of the extension of the disease,
 — locating the primary tumour,
 — planning the surgical treatment,
 — assessment of the response to treatment,
 — qualification for radioisotope therapy.
2.3.1. Ultrasonography
2.3.1.1. Transabdominal ultrasonography
USG examination, due to its high availability and low 
cost, is usually the first imaging test performed. The 
sensitivity of the test depends on the tumour location, 
experience of the physician and on anatomical and 
technical conditions [1].
In clinical practice, USG examination is used mostly 
in the preliminary diagnostics of pancreatic endocrine 
tumours and of hepatic metastases. Due to technical 
*evidence level according to OCEBM [274]
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limitations, USG is not useful in the assessment of other 
parts of the gastrointestinal tract [1].
The image of NEN in a USG examination is non- 
-specific. The tumour is often well-circumscribed, hy-
poechogenic, sometimes with a hyperechoic capsule, 
foci of necrosis, and calcifications. However, the tumour 
may also be hyperechoic or isoechoic. Most tumour 
foci in a Doppler examination demonstrate extensive 
vascularisation [1].
The sensitivity of transabdominal USG in the diag-
nostics of metastatic foci in the liver ranges from 82% 
to 88%, and specificity is between 92% and 95% [56]. 
The sensitivity of the method in the diagnosis of pancre-
atic tumours is much lower at 39% (17–79%) [47, 57, 58]. 
Using contrast material in the ultrasonographic diag-
nostics of NEN (contrast enhanced ultrasonography, 
CEUS) is very useful; 78–86% of tumour foci dem-
onstrate contrast enhancement in the arterial phase. 
The sensitivity of CEUS in the diagnostics of hepatic 
metastases rises to 99% [59].
2.3.1.2. Endoscopic ultrasonography
Currently, the basic examination used in the diagnos-
tics of NENs of the pancreas and rectum is endoscopic 
ultrasonography (EUS). The small distance between the 
source of the ultrasound and the object studied enables 
the use of ultrasonic waves of higher frequency than 
in a conventional USG device, which results in a much 
better image resolution [1].
Accepted indications for EUS include assessment of 
local advancement of neoplastic lesions in the gastroin-
testinal tract, diagnostics of submucosal lesions and of 
diseases of the pancreas and bile ducts. The examination 
enables visualisation of small-volume lesions, and as-
sessment of regional lymph nodes. This method allows 
for precise determination of anatomical relations (i.e. 
tumour location relative to the bile ducts and main ves-
sels) and assessment of the depth of gastrointestinal wall 
infiltration [1]. EUS examination is particularly useful in 
the diagnostics of pancreatic NENs (due to their typically 
small size). The sensitivity of the method depends on 
the location of the tumour: for tumours located in the 
head and body of the pancreas, it is approximately 90% 
(77–100%) [50, 52–55, 60], for tumours located peripher-
ally it is 75–80% [47, 57]. The specificity of the method is 
estimated at 98% [61]. In the diagnostics of the neoplastic 
foci located in the pancreas in high-risk patients, EUS is 
more sensitive than CT [60].
Transrectal EUS is the most sensitive method for 
pre-operative assessment of the stage of rectal tumour 
advancement; its sensitivity in the assessment of the tu-
mour and invasion of the rectum wall is 76–93%, and of 
the regional lymph nodes metastases it is 61–88% [62, 63]. 
Intra-operative ultrasonography
Intra-operative ultrasonography (IOUS) is used 
primarily to diagnose focal lesions in the pancreas. The 
sensitivity of this technique is 90% (74–96%), especially 
in combination with intra-operative palpation assess-
ment [64, 65, 66].
Intraductal ultrasonography
Mini-probes may be introduced through the endo-
scope biopsy channel into the pancreatic duct or bile 
duct. This technique enables the assessment of the 
inside of the duct and of its wall (intraductal sonogra-
phy, IDUS). It allows better visualisation, compared to 
EUS, of pancreatic NEN in the immediate vicinity of the 
pancreatic duct, and of the endo-luminal lesions. The 
sensitivity of this examination is approximately 94% 
[67], and it increases to almost 100% for lesions larger 
than 3 mm located in the pancreatic duct [68, 69].
2.3.2. Endoscopic examinations
Endoscopy is the basic method in the diagnostics of 
neuroendocrine neoplasms originating in the gastric 
or duodenal wall [70].
Using colonoscopy as a tool for colorectal cancer 
enables diagnosis of GEP NEN lesions in the colon and 
rectum. These are usually found accidentally, during 
examinations performed due to non-specific symp-
toms, such as dyspepsia or anaemia, or during screen-
ing tests. GEP NEN lesions are usually in the form of 
polypoid mucosal elevation, and only histopathological 
examination enables proper diagnosis to be achieved 
[4, 71]. The size of the lesion, degree of gastrointestinal 
wall infiltration, and potential presence of locoregional 
metastases determine the therapeutic strategy, and can 
be assessed based on an EUS examination. This test also 
allows specimens to be obtained for histopathological 
assessment [4, 72].
Panendoscopy (oesophago-gastroduodenoscopy, 
upper gastrointestinal endoscopy) and colonoscopy 
with ileoscopy are frequently the first examinations to 
be performed in patients with suspected or diagnosed 
NENs of unknown origin, after lymph node or hepatic 
metastases are found [1, 71]. This situation is especially 
common with neuroendocrine tumours originating in 
the small intestine. The location of the primary tumour 
site may be important for the choice of optimal manage-
ment, despite a diagnosis based on the histopathological 
and immunohistochemical examination of the material 
obtained in targeted biopsy of the metastases.
In the case of any doubt, an upper gastrointestinal 
examination with an endoscope with lateral optics is 
recommended because it enables a better evaluation 
of the hepatopancreatic ampulla (ampulla of Vater) 
*evidence level according to OCEBM [274]
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area. A properly performed endoscopic examination in 
the search for the original tumour site in patients with 
hepatic metastases enables the detection of nearly 100% 
of primary lesions located in the stomach, and 86% of 
lesions in the large intestine [5, 73, 74].
Currently, capsule endoscopy and enteroscopy en-
able examination of the small intestine. Video Capsule 
Endoscopy (VCE), or Wireless Endoscopy, is a non-inva-
sive examination of the small intestine performed with 
a single-use, wireless capsule. Swallowed by the patient, 
the capsule passively moves through the gastrointesti-
nal tract, allowing the assessment of the small intestinal 
mucosa along its entire length. This examination does 
not substitute gastroscopy or colonoscopy. Contrary to 
a traditional endoscope, the current capsules are not 
steerable, so repetitive assessment of a chosen part of 
the intestine is impossible [5, 75, 76]. The limitation of 
capsule endoscopy is the run-time of its battery, which 
means that in some patients with disturbed peristalsis 
the latter part of the ileum may remain unexamined. 
The most common complication (0.75% of all patients) 
is capsule incarceration in the narrowing of the small 
intestine resulting from the use of non-steroidal anti-
inflammatory drugs, or due to other diseases such as 
Crohn’s disease. Also, small intestinal NENs, due to 
secreted growth factors which lead to desmoplastic 
reactions of the mesentery, may result in a significant 
intestinal narrowing [1, 77]. Current reports indicate 
a relatively low sensitivity of the test with the use of an 
endoscopic capsule in the detection of midgut lesions, 
especially in the detection of submucosal and eccentric 
lesions; the sensitivity is approximately 45%. Small 
intestinal tumours are diagnosed mostly by accident, 
during the diagnostics for gastrointestinal haemor-
rhage, for example [1, 7, 77, 78].
Balloon enteroscopy (single-balloon, double-bal-
loon) or spiral enteroscopy [1, 79] enable assessment 
of the small intestine and obtaining tissue material for 
a histopathological examination with the possibility of 
endoscopic treatment. While conducting the examina-
tion, it is possible to use EUS with miniature heads with 
an external diameter of 2 or 2.6 mm, introduced through 
the enteroscope biopsy channel [1, 10, 80].
Capsule endoscopy and balloon enteroscopy are 
complementary methods. Non-invasive capsule en-
doscopy enables initial location of the tumour, while 
enteroscopy helps to obtain material for histopathologi-
cal examination and to conduct therapeutic procedures 
[1, 79, 81].
Complete assessment of the small intestine via ent-
eroscopy is achieved in approximately 80% of patients. 
The diagnostic effectiveness of the examination is ap-
prox. 55% [82–84].
2.3.3. Computed tomography
Computed tomography examination is currently the 
standard method to assess the location of tumour foci 
and to determine NEN staging. CT is also used to moni-
tor the effects of treatment. However, this examination 
demonstrates relatively low sensitivity in locating the 
primary tumour site if the patient is not properly pre-
pared for the test [1, 85].
Currently, spiral MDCT (multi-detector computed 
tomography) devices are in common use. Depending 
on the manner of filling the gastrointestinal lumen, the 
examination is referred to as CT enterography (if the 
patient receives low-absorption contrast material), or 
CT enteroclysis (if it is administered using a probe in-
troduced into the small intestine). After proper filling of 
the gastrointestinal tract, a CT examination is performed 
before and after the administration of the contrast 
material. Scanning after intravenous administration of 
contrast should be conducted in two phases — arterial 
and portal venous, over all of intestines and of the liver 
to detect possible metastases [1].
Symptoms indicating malignancy of the tumour 
include: large volume, necrosis, and characteristics 
of infiltration of adjacent tissues (lesions occur in ap-
proximately 20% of patients). In the arterial phase, 
hyperdense lesions are most frequently found; rarely 
are they hypovascularised or cystic. In the portal venous 
phase, NETs are mostly hypodense lesions because the 
contrast material is quickly washed out [1].
The sensitivity of the CT examination in the diagnos-
tics of pancreatic tumours is 73% (63–82%), and specific-
ity is 96% (83–100%) [1, 86–88]. The test’s sensitivity in 
the assessment of hepatic metastases is 82% (78–100%), 
and the specificity is 92% (83–100%) [1, 47, 89–91]. The 
sensitivity of the CT examination in the diagnostics of 
extrahepatic metastases is 75% (63–90%), and the spec-
ificity is 99% (98–100%) [1, 47].
In the monitoring of the response to treatment, it is 
recommended to apply both anatomic and functional 
methods as the sensitivity and specificity of individual 
tests is insufficient [92].
CT colonography
Computed tomography also enables virtual colonos-
copy (VC). This method allows for three-dimensional 
imaging of the walls and content of the large intestine. 
For perfect 3D reconstructions, it is necessary to use 
a submillimetre layer thickness [1].
The patient requires proper preparation, similarly 
to traditional colonoscopy. The preparation consists of 
complete emptying of the large intestine from faecal 
masses and liquid (residual faecal masses may result 
in false-positives) [1, 93].
*evidence level according to OCEBM [274]
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Full assessment of the examination includes the 
analysis of topical scan and axial cross-section im-
ages (treated as reference images), and the analysis of 
multiplanar and three-dimensional reconstructions 
(including 3D algorithms of the navigator type). A 
novel feature that improves the effectiveness of result 
interpretation is computer aided diagnosis (CAD) [1].
CT colonography is a safe and well-tolerated diag-
nostic method. The sensitivity and specificity of the 
method is comparable to classical colonoscopy.
The sensitivity of CT and endoscopic colonography is 
similar; according to different authors it is 90% for lesions 
> 10 mm and 85% for lesions > 6 mm; the sensitivity and 
specificity in the diagnostics of malignant neoplasms is 
88–100%, and in benign neoplasms is 86% [94, 95].
The quality of the obtained images depends on 
patient co-operation and preparation [93].
2.3.4. Magnetic resonance imaging
The sensitivity and specificity of magnetic resonance 
imaging (MRI) are similar to CT in the diagnosis of the 
primary focus and metastases of NENs [96]. The exami-
nation protocol includes performance of the following 
images/sequences:
 — T1-weighted (spin-echo, SE),
 — T1-weighted with fat saturation,
 — T1-weighted (gradient echo, GRE) after adminis-
tration of the contrast material (dynamic and static 
examination), thin axial layers, 
 — 3D T1 GRE, with fat saturation — before and after 
i.v. administration of the contrast material, 
 — T2-weighted (fast spin-echo, FSE), T2-weighted with 
fat saturation [97], 
 — DWI with ADC mapping.
Tumours demonstrate a hypointense signal in 
T1-weighted images, and a hyperintense signal in T2-
weighted images (rarely hypointense — if they contain 
a large fibrous tissue component), and they are strongly 
enhanced after administration of the contrast material. 
Cystic tumours with necrotic foci are ring-enhanced. 
75% of metastatic foci in the MRI scan demonstrate 
a hypointense signal in T1-weighted ima ges, most 
being strongly enhanced after administration of the 
contrast material. The MRI technique also enables 
a CT colonography-type examination to be conducted. 
The advantages and disadvantages of this method are 
similar to those of CT colonography [1].
MRI — following the optimal protocol — allows 
the diagnosis of 80–95% of metastatic foci in the 
liver [91, 95, 98, 99], and 73–93% of pancreatic NENs 
[91, 100]. In the diagnostics of extra-pancreatic and 
extra-hepatic foci, the test’s sensitivity is much lower, 
i.e. 68–89% [101, 102].
Whole-body MRI is considered to be a second-line 
test in the assessment of hepatic metastases smaller than 
10 mm, and in the assessment of foci with non-specific 
enhancement on the CT scan. It is also recommended 
in patients allergic to the iodine contrast agents used 
in CT imaging [1].
There are also studies describing the use of DWI 
sequence for whole-body examinations in patients with 
neuroendocrine tumours, as a particularly sensitive 
method in the detection of metastases [103, 104].
2.3.5. CT/MRI enteroclysis/enterography
Currently, to assess the small intestine, CT/MRI 
enterography/enteroclysis are used. These methods 
increase the CT sensitivity even to 100% [85, 105, 106].
The techniques enable the identification of even 
small, segmental thickening of the intestinal wall, small 
intramural nodules, and segmental narrowing of the lu-
men. The MRI examination provides better tissue reso-
lution than CT; it enables assessment of intestinal wall 
layers and of the level of its infiltration by the tumour. 
The scope of the examination should include the field 
from the level of the liver to the pubic symphysis [1].
In CT/MRI enteroclysis, the contrast medium is 
administered through a probe introduced under fluo-
roscopic control beyond the duodenojejunal angle. An 
anti-reflux balloon prevents a reflux of the contrast ma-
terial into the duodenum. After the contrast material has 
been administered, an MRI examination of the abdominal 
cavity is performed, using a surface coil. Fast T1-weight-
ed and T2-weighted sequences should be performed 
(e.g. HASTE, FIESTA), as well as T2-weighted sequences 
with fat saturation, and examination after intravenous 
administration of the contrast material (T1-weighted 
images) should show the layers to be 3–5 mm thick. As 
a standard procedure, the patient should be in the supine 
position (the prone position is uncomfortable, and the pa-
tient cannot stay in it for long; therefore, it is rarely used, 
generally only if artefacts are present). In CT enteroclysis, 
following the filling of the intestinal lumen with a negative 
contrast medium (e.g. an aqueous Lactulose solution), an 
intravenous contrast material is administered, 1.5–2 ml/kg, 
at 3–4 ml/s. The test is performed in the arterial phase 
starting with the smart prep function with a 30–60-s delay 
(from 45 seconds — intestinal phase), the layers should 
be 1–3.0 mm thick [1, 85].
In CT/MRI enterography, the contrast material is 
administered orally, an hour before the examination. In 
MRI, intravenous administration of medicines slowing 
intestinal peristalsis is recommended (e.g. 1 ampoule 
of Buscolysin 20 mg in 1 ml; either intravenous or in-
tramuscular administration are possible if the patient 
has no contraindications) [1].
*evidence level according to OCEBM [274]
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MRI enteroclysis provides a better level of exten-
sion of the intestinal loops and the ability to assess 
peristalsis; however, the patient’s tolerance to the test 
is lower compared to enterography. Sensitivities of CT 
enterography and enteroclysis are similar. Due to the 
long duration of the data acquisition process in MRI, 
enteroclysis is recommended for this test [1, 85]. Recent 
studies report that in MRI enteroclysis a sensitivity of 
86–94% is achievable, and a specificity of 95–97% in the 
detection of small tumours in the small intestine [106].
The examination time in CT enteroclysis is shorter 
than in MRI enteroclysis. Therefore, the quality of the 
test is less dependent on co-operation with the patient. 
However, it is associated with the patient’s exposure to 
ionizing radiation [1].
Minimal consensus on imaging examination:
The choice of imaging examination depends on the pri-
mary focus location and the stage of the disease: USG, CT, 
MRI, endoscopy (*evidence level 3–4).
Detailed tests for individual organs are discussed in later 
sections.
2.4. Radioisotope diagnostics
2.4.1. Radioisotope-labelled somatostatin analogues 
imaging
Radioisotope-labelled somatostatin analogues are the 
most sensitive method of diagnostic imaging for NETs. 
Somatostatin receptor imaging (SRI) is performed 
using scintigraphy (planar examination, SPECT, or 
SPECT/CT), or using positron emission tomography 
PET/CT. The sensitivity of SRI depends on the method 
(it is the highest in PET/CT examination). For most 
types  of GEP NET and locations the SRI sensitivity 
images between 54 and 100% [107–115]. Insulinoma is 
an exception, as somatostatin receptor overexpression 
is found in 50–60% of cases [116].
Clinical indications for SRI are: location of the 
primary tumour, determination of the stage of the 
disease, monitoring of the patient following radical 
surgical treatment, assessment of the effectiveness of 
the applied treatment, and qualification of patients 
for antiproliferative treatment with SSA and targeted 
radioisotope therapy [1].
As the CLARINET study showed the antiprolifera-
tive effect of lanreotide in the presence of somatostatin 
receptors with an uptake at least comparable to that of 
the liver, an SRI should be performed before introduc-
ing antiproliferative SSA [117].
In 2017, a new classification for neuroendocrine 
neoplasms NEN has been introduced, comprising 
NETs G1, G2, and G3, and NECs [31–35]. Previously 
published data refer to NETs G1 and G2. There is no 
data available on the imaging of somatostatin recep-
tors in NETs G3. Considering the well-differentiated 
character of NET G3 neoplastic cells, it seems justified 
to conduct examinations using 68Ga-somatostatin ana-
logues for the diagnostics of this group. In the case of 
NECs, imaging examination of somatostatin receptors 
is not performed routinely; however, it may be useful 
before deciding on the introduction of SSA treatment.
2.4.1.1. Isotope diagnostics using indium-labelled  
111In-pentreotide (OctreoScan®)
In 1994, the USA Federal Drug Administration (FDA) 
authorised indium-labelled 111In-pentreotide (Octre-
oScan®) for marketing. This compound demonstrates 
a high affinity to SSTR2, a much lower affinity to SSTR5 
and SSTR3, and no affinity to SSTR1 and SSTR4 [1, 118]. 
The sensitivity of receptor scintigraphy with the use 
of 111In-pentreotide is 54–86%, with an average of 80% 
[108, 109]. Currently, due to the higher sensitivity of tests 
with other tracers, lower dose absorption by the patient, 
and the duration and cost of the examination, in most 
centres the use of 111In-pentreotide has been abandoned.
2.4.1.2. Diagnostics imaging with technetium-labelled 
somatostatin analogues (99mTc)
99m-technetium (99mTc)-labelled somatostatin analogues 
are increasingly used in the radioisotope diagnostics of 
NETs [1, 112, 119–121]. The physical properties of 99mTc 
significantly increase the quality of imaging, compared 
to 111In-pentreotide. Currently, the standard in imaging 
examinations is the WB-SPECT technique, including ac-
quisition of the test in the SPECT tomographic technique 
using CT (WB-SPECT/CT) for attenuation correction, and 
for structural location with CT. The examination concerns 
structures similar to those in the PET technique.
Limited scientific reports demonstrate a higher 
sensitivity of the scintigraphic examination with the 
use of 99mTc-HYNICTOC compared to 111In-pentreotide 
[122]. Due to the positive Polish experience with 
99mTc-HYNICTOC (Tectrotide®) and 99mTc-HYNICTATE, 
scintigraphy with the use of 111In-pentreotide has been 
completely substituted by this method in those centres 
that do not offer positron emission tomography, in 
Poland and in many other European countries [51, 
120, 121]. This is due to shorter time of examination, 
lower patient exposure, and every day availability of 
99mTc-HYNICTOC (Tectrotide®), and 99mTc-HYNICTATE 
in a nuclear medicine laboratory. 
2.4.1.3. Diagnostics imaging with positron emitting 
tracer-labelled somatostatine analogues
Of all radioisotope examinations, scintigraphy using 
positron-emitting tracers offers the highest resolution. 
Literature data suggest higher sensitivity of scintigraphy 
*evidence level according to OCEBM [274]
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with somatostatin analogues labelled with positron 
emitting tracers (68Ga) compared to the SPECT test with 
111In-pentreotide or 99mTc- HYNICTOC [1, 107–115, 123]. 
The somatostatin analogues currently in use include 
DOTATATE, DOTATOC, and DOTANOC, which dif-
fer in their affinity to individual SSTRs. The sensitivity, 
specifi city, and diagnostic accuracy in PET examinations 
using 68Ga-labelled somatostatin analogues are 97%, 92%, 
and 96%, respectively [1, 52, 124, 125]. The sensitivity of 
68Ga-DOTATATE PET/CT demonstrated in a meta-anal-
ysis comprising 10 studies was 90.9% (95% CI: 81.4%, 
96.4%), and its specificity was 90.6% (95% CI: 77.8%, 
96.1%) [115]. PET/CT with 68Ga-labelled somatostatin 
analogues is particularly useful in the detection of the pri-
mary lesions, in the pre-operative exclusion of metastases, 
and in the assessment of somatostatin receptor expression 
before a planned radioisotope treatment. PET/CT with 
68Ga-labelled somatostatin analogues is more sensitive 
than a classical scintigraphic examination in the detec-
tion of occult or clinically suspected osseous metastases, 
which is the fourth most frequent location of metastases, 
or lymph node metastases. PET/CT with 68Ga-labelled 
somatostatin analogues significantly affects the change 
of treatment in 13–71% of patients [107, 124, 126–128].
Moreover, in a PET/CT with Ga-DOTA somatostatin 
analogues, it is possible to measure the standardised 
uptake value (SUVmax). The SUVmax value is corre-
lated with the density of somatostatin receptors present 
on the cell surface, which is crucial in establishing the 
patient’s eligibility for the treatment with labelled so-
matostatin analogues (PRRT) [129]. Eligibility for PRRT 
includes patients with tumour/metastases uptake of 
at least the same intensity as that in the liver, i.e. a the 
Krenning score of 2 [130].
The reference organ used to obtain the value (the 
liver) demonstrates the lowest physiological accumula-
tion rate of all organs [131].
Therefore, the best results for PRRT treatment are 
achieved when the uptake in the metastatic lesions is 2.2 
times higher than in the liver, or SUVmax > 16.4 [132]. In 
centres with a PET scanner, examination with 68Ga-labelled 
somatostatin analogues should be the test of choice.
Recently, 64-copper (64Cu)-labelled SSA has also been 
used in examinations [133, 134]. Due to its longer half-
life, 64Cu enables images to be obtained even 24 hours 
after administration of the tracer. Currently, no conclu-
sive data are available to demonstrate any advantage 
of 64Cu-DOTATATE over the 68Ga-labelled somatostatin 
analogues currently in use [134].
2.4.1.4. Intra-operative imaging of somatostatin analogues
Due to the use of intra-operative scintillation probes, it 
is possible to visualise somatostatin analogues intraope-
ratively. The examination is useful in the visualisation of 
the primary lesion, and in the detection of metastases 
to regional lymph nodes, significantly facilitating and 
shortening the surgical procedure. Intra-operative exa-
mination involves 99mTc- or 68Ga-labelled somatostatin 
analogues [135, 136].
2.4.2. Radioisotope diagnostics with  
fluorodeoxyglucose 18FDG
So far, PET/CT with the use of radioisotope-labelled 
18F-fluorodeoxyglucose (18FDG) was considered to be 
of limited value in the diagnostics of NETs, due to its 
low sensitivity. However, it has been demonstrated 
that collection of 18FDG in neoplastic foci is a significant 
negative prognostic factor, enabling a more precise 
characterisation of the biological tumor malignancy 
[137–140]. Results of PET/CT with 18FDG are positive 
in approximately 30% of NET G1, 60% of NET G2, and 
over 80% of NECs [141, 142]. A statistically significantly 
shorter progression-free survival (PFS), as well shorter 
overall survival (OS), were found in patients with posi-
tive 18FDG PET/CT result [138, 143]. An arbitrary value 
of SUVmax > 2.5 is frequently associated with a more 
aggressive course of the disease and should be the basis 
for prompt introduction of second line therapy [138].
Due to the diverse biological properties of neuroen-
docrine neoplasms, PET/CT with 18FDG and assessment 
of somatostatin receptor expression in SRI are necessary 
to properly qualify the patient for radioisotope treat-
ment [138].
2.4.3. Radioisotope diagnostics with radioisotope-
-labelled dihydroxyphenylalanine 18F-DOPA
PET diagnostics with dihydroxyphenylalanine (DOPA) 
labelled with fluorine-18 (18F-DOPA) is a promising 
method in the imaging of NETs [1]. 18F-DOPA PET/CT 
has demonstrated a sensitivity of 65–96% in the diagno-
sis of NETs [144–146]. However, the role of this examina-
tion is not conclusive [139, 146–148]. It would appear to 
be useful in the case of functional pancreatic tumours 
and in other GEP NETs, if SRI is negative [145, 148].
2.4.4. Diagnostics with radioisotope-labelled  
meta-iodobenzylguanidine 123/131I-MIBG
Another tracer used in the diagnostics and therapy 
of NEN is guanidine derivative labelled with iodine, 
meta-iodobenzylguanidine (123/131I-MIBG), which 
is accumulated in cells via the VMAT1 and VMAT2 
mechanism.
Imaging with the use of 123/131I-MIBG is performed 
primarily in pheochromocytoma and neuroblastoma, 
and rarely in other neoplasms of neuroendocrine origin. 
The sensitivity of 123/131I-MIBG scintigraphy in NETs is 
*evidence level according to OCEBM [274]
92
Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms Kos-Kudła Beata et al.
SZ
K
O
LE
N
IE
 
PO
D
YP
LO
M
O
W
E
approximately 50% (40–85%) and is lower than that with 
111In-pentreotide imaging [149, 150]. The best results are 
achieved using 123I-MIBG in the visualisation of hepatic 
metastases. However, in this case, receptor scintigraphy is 
more sensitive [150]. Therefore, 123/131I-MIBG scintigraphy 
is currently primarily performed in patient qualification 
for isotope 131I-MIBG treatment, if SRI is negative [1].
2.4.5. Other radioisotope tracers
Apart from the above radiotracers, numerous stud-
ies are currently being conducted, such using like 
11C-5-hydroxytryptophan (11C-HTP), or other new re-
ceptor tracers such as glucagon-like peptide-1 (GLP1) 
analogues in the case of insulinoma, and gastrin or 
bombesin analogues in the case of medullary thyroid 
carcinoma [151–155].
Particularly promising are the GLP-1 analogues in 
the diagnostics of insulinoma. GLP-1 analogues labelled 
with 111In, 99mTc, and 68Ga have been used in several 
studies [151, 153, 155]. The initial results indicate the 
lack of GLP-1 receptor expression in the majority of 
malignant insulinomas (where usually SRI is positive), 
which suggests the usefulness of imaging with labelled 
GLP-1 analogues in the differentiation of benign and 
malignant forms of insulin tumours [151, 153].
However, due to limited availability, these tracers 
are not used in routine diagnostics.
Minimal consensus statement on radioisotope exa-
minations:
 — Somatostatin receptor radioisotope imaging (SRI) us-
ing PET/CT with radiolabelled somatostatin analogues 
with 68Ga, and in those centres which do not have a PET 
scaner — SPECT/CT (SPECT) with 99mTc radiolabelled 
somatostatine analogues; for determination of the primary 
tumour site, assessment of the disease stage, assessment of 
the treatment results, and qualification for PRRT therapy/ 
/antiproliferative treatment with SSA (*evidence level 2).
 —  18FDG- PET/CT for NECs, in qualification for radioiso-
tope treatment and for rapidly growing NETs (*evidence 
level 3).
3. Treatment
3.1. Surgical treatment
In GEP NENs the treatment of choice is surgical manage-
ment, the scope of which depends on the patient’s general 
condition and on tumour location, stage, and specificity 
(biology) of the neoplasm (*evidence level 4) [1, 6].
Unlike in most frequent gastrointestinal adenocarci-
nomas, due to the diverse biology and clinical presenta-
tion of GEP NENs, methods used for their treatment 
and indications for their surgical management in differ-
ent parts of the gastrointestinal tract will be discussed 
in detail in the following sections of this document.
Tumour diameter is one of the main parameters 
when deciding on the treatment of non-functional GEP 
NENs (especially NETs G1 and G2). Small lesions (tu-
mour size limits are determined for individual organs) 
may be treated conservatively or observed, whereas 
larger neoplasms should be treated surgically, with 
removal of the lymph nodes [156]. Functional tumours 
should be resected regardless of the size of the lesion.
In GEP NENS, in particular NET G3 and NECs, i.e. 
neuroendocrine tumours with a proliferation index of 
over 20% (Table V), the same management principles 
should be applied as in other malignant gastrointestinal 
neoplasms [157]. In clinical stages I, II, and III, radical 
therapy (with the intension to cure) is applied. In clini-
cal stage IV, when the neoplasm dissemination (distant 
metastases present, e.g. in the liver or lungs), palliative 
treatment can be introduced to improve the quality of 
life and/or extend patient survival.
In stage IV G1-G2 GEP NETs with M1 feature in 
the liver the surgical procedure does not have to be 
tantamount to palliative treatment [158]. Radical re-
section of the primary tumour and hepatic metastases 
can have a curative effect and is the best therapeutic 
option [159] (*evidence level 2). Resection of the metas-
tases should be accompanied by removal of regional 
lymph nodes [158].
Cytoreduction of hepatic metastases should be con-
sidered in patients with functional tumours and uncon-
trolled symptoms, and in patients with non-functional 
tumours and symptoms related to the tumour, if the 
disease is stable for over 6 months. Cytoreduction is 
indicated for better symptom control, especially if the 
tumour mass can be reduced by 90% [158, 160] (*evi-
dence level 2). If metastases cannot be resected, ablation 
techniques should be considered (embolisation, chem-
oembolisation, RFA, and SIRT) [158]. The principles of 
treatment of NEN metastases to the liver are presented 
in Figure 2 [161].
In the case of NENs with a proliferation index 
above 20%, especially above 55%, and with advanced 
metastases, resection, cytoreduction, or ablation of 
the hepatic metastases are not recommended [157].
A specific form of palliative treatment of NET is 
cytoreductive therapy, which consists of reduction of 
the neoplasm mass in order to reduce the symptoms 
and obtain better effects of systemic treatment if hepatic 
metastases are present [156].
Resection of stage IV primary tumour with non- 
-resectable hepatic metastases is under consideration 
[162] (*evidence level 3).
*evidence level according to OCEBM [274]
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3.1.1. Indications for liver transplantation in GEP NETs
Liver transplantation in patients with GEP NET 
should be considered if non-resectable neoplastic le-
sions are found in the liver parenchyma, both primary 
and metastatic. This method of treatment is also indi-
cated in patients with hepatic recurrence of neoplastic 
disease, after liver resection, ablation therapy, or sys-
temic treatment due to GEP NET [1, 163]. Liver trans-
plant may be performed in the case of symptomatic or 
non-symptomatic tumours [1, 164, 165].
Qualification for liver transplantation depends on 
confirmation of exclusively hepatic location of the me-
tastases of the primary GEP NET (no extra-hepatic me-
tastases in imaging examinations, PET/CT, or diagnostic 
laparoscopy/laparotomy) and on its histopathological 
grade of G1 or G2 according to the WHO classification 
system [164] (*evidence level 3). Prior to liver transplanta-
tion, removal of the primary focus is also recommended 
(especially in the case of pancreatic NET). It should be 
noted that a Ki-67 of < 10% provides the most favour-
able prognosis (*evidence level 3) [164, 166]. The viability 
of qualification of young patients and those who have 
exhausted the options of symptomatic treatment is 
emphasised [158].
Adverse prognostic factors for survival include in-
filtration of the large hepatic vessels and simultaneous 
resection of the neoplasm outside the liver [166].
Minimal consensus statement of surgical manage-
ment:
 — In GEP NETs, the treatment of choice is surgical manage-
ment, the scope of which depends on the patient’s general 
condition and on the location, stage, and biology of the 
neoplasm (*evidence level 4).
 — Tumour diameter is one of the main parameters when 
deciding on the treatment of non-functional GEP NETs 
(G1, G2). Small lesions may be treated conservatively 
or observed, whereas larger neoplasms should be treated 
surgically, with removal of the lymph nodes (*evidence 
level 2). Functional tumours should be resected regardless 
of the size of the lesion.
 — In the case of GEP NETs G1-G2 with metastases in the 
liver, radical resection of the primary tumour and the 
hepatic metastases is the best therapeutic option. Resec-
tion of the metastases should be accompanied by removal 
of the regional lymph nodes. In NET G3 and NECs, the 
same principles of oncological management should be ap-
plied as that in other gastrointestinal neoplasms. In the 
case of NENs with a proliferation index above 20% and 
with advanced metastases, resection, cytoreduction or 
ablation of the hepatic metastases are not recommended 
(*evidence level 3).
 — Cytoreduction of hepatic metastases should be consi-
dered in patients with functional tumours and uncon-
trolled symptoms, and in patients with non-functional 
tumours and symptoms related to the tumour, if the 
disease is stable for over 6 months. If metastases cannot 
be resected, ablation techniques should be considered.
 — A form of palliative treatment for GEP NETs is cytore-
ductive therapy which consists of the reduction of the 
neoplasm mass in order to reduce the symptoms and obtain 
better effects of systemic treatment if hepatic metastases 
are present (*evidence level 3).
 — Liver transplant should be considered in certain patients 
with non-resectable G1 or G2 GEP NETs in the liver 
parenchyma, if metastases outside the liver are not found 
(*evidence level 3).
3.2. Endoscopic treatment
The main purpose of the treatment of GEP NENs 
is complete removal of the tumour, and, in the case 
of functional tumours, also control of the clinical 
symptoms associated with the production of specific 
hormones [1].
Although the basic method of radical treatment is 
surgical resection, technological progress in endoscopic 
equipment and development of new therapeutic en-
doscopic techniques justify the use of this treatment 
in certain cases. This is possible mainly due to the 
introduction of methods such as endoscopic ultra-
sonography which enables precise assessment of the 
gastrointestinal tract wall and its individual layers with 
surrounding structures, and adequate qualification of 
patients for endoscopic or surgical procedures, as well 
as endoscopic mucosal resection (EMR) and endoscopic 
submucosal dissection (ESD) [1, 167–169]. The thera-
peutic approach to GEP NENs located in the upper 
gastrointestinal tract and in the large intestine, often 
detected during diagnostic endoscopic examination, 
depends on the tumour size, depth of invasion, and 
the presence of metastases at the diagnosis. Endoscopic 
resection of GEP NENs may be used as a treatment 
method only in well-differentiated G1 and T1 tumours, 
according to the TNM classification. Before deciding on 
endoscopic treatment, endosonographic examination 
is necessary to determine the size of the lesion and 
the depth of infiltration into the gastrointestinal tract 
wall, as well as to assess the regional lymph nodes. The 
test may be completed with fine-needle biopsy of the 
primary lesion and lymph nodes. Only lesions limited 
to the mucosa and submucosa qualify for endoscopic 
removal, while in all other cases local or radical surgi-
cal excision is recommended, possibly with supporting 
therapy or chemotherapy [1].
It is estimated that approximately 20% of gastric 
NENs, 10% of duodenal NENs, and as many as 70% 
of rectal tumours qualify for endoscopic removal [170].
*evidence level according to OCEBM [274]
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Classical polypectomy performed with the use 
of electrocoagulation loop is not recommended as 
a therapeutic method in GEP NENs, as it often leaves 
a positive margin after the procedure. The optimum 
method is endoscopic mucosal resection or endo-
scopic submucosal dissection. Endoscopic resection 
conducted by the injection and cut technique consists 
in lifting of the lesion from the muscular layer of the 
wall by injection of a substance to create a “bubble” 
under the lesion, and in subsequent removal of the 
lesion with a diathermic loop. Lifting of the lesion is 
a condition for qualifying for this procedure; the ab-
sence of this phenomenon (non-lifting sign) indicates 
infiltration of the deeper layers of the gastrointestinal 
tract wall, and is a contraindication for endoscopic 
resection. Other EMR techniques include injection, 
lifting and section (strip biopsy), endoscopic mucosal 
resection with ligation (EMR-L) or cap assisted endo-
scopic mucosal resection (EMR-C). Lesions limited to 
the mucosa, well-differentiated, convex, smaller than 
2 cm and without ulceration qualify for endoscopic 
resection [1, 171].
Endoscopic submucosal dissection is a technique 
which enables the removal of lesions of diameter greater 
than 3 cm in one piece (en-block) within the normal 
tissue. It involves marking by means of electrocoagu-
lation of the mucosa surrounding the lesion, injecting 
a solution into the submucosal membrane and lifting 
the lesion above the muscularis propria, performing 
a circular dissection of the lamina propria mucosa 
around the lesion, and removing the lesion together 
with the submucosal membrane [172–176].
The most common complications following mucosal 
resection and endoscopic submucosal dissection are 
haemorrhage (up to 7%) and perforation (5%). They 
are more frequent in duodenal or gastric lesion removal 
than in rectal lesions. A submucosal dissection, com-
pared to mucosal resection, is characterised by a higher 
size-independent ratio of the lesions removed en-bloc 
(OR 13.87), and a lower local recurrence ratio (OR 0.09), 
but this technique takes longer to perform and leads 
to a higher rate of complications (haemorrhage OR 2.2; 
perforation OR 4.09) [177]. Due to the higher rate of R0 
resections, ESD should be the method of choice in the 
endoscopic treatment of NENs [178].
The radicality of an endoscopic procedure is de-
termined by the following histopathological criteria: 
complete removal of the lesion (negative margins), 
absence of angioinvasion, as well as low mitotic activ-
ity and low proliferation index. In the majority of cases 
further surveillance is recommended after endoscopic 
treatment, although detailed monitoring principles 
have not been established in all cases [179].
Endoscopic methods can also be used in palliative 
treatment of NEN in the case of:
 — mechanical jaundice due to pressure on biliary ducts 
(prosthesis of the biliary ducts);
 — obstruction of the gastrointestinal tract (prosthesis 
of the gastrointestinal tract);
 — gastrointestinal bleeding (endoscopic methods for 
stemming bleeding);
 — pain (EUS-controlled solar plexus neurolysis);
 — functional tumours with clinical symptoms (EUS-con- 
trolled ablation in patients at high risk of surgical 
treatment) [180, 181].
Minimal consensus statement for endoscopic treatment:
 — In certain clinical situations (a well-differentiated gas-
tric, duodenal, and rectal G1 and T1 tumour, according 
to the TNM classification), endoscopic methods such as 
endoscopic mucosal resection (EMR) and endoscopic sub-
mucosal dissection (ESD) may provide a beneficial alter-
native to surgical treatment. Endoscopic ultrasonography 
(EUS) enables precise assessment of the gastrointestinal 
tract wall and its individual layers with surrounding 
structures, as well as adequate qualification of patients 
for endoscopic or surgical procedures.
 — Endoscopy also enables palliative treatment of mechanical 
jaundice due to pressure on the biliary ducts, obstruction 
of the gastrointestinal tract, gastrointestinal haemorrhag-
ing, pain (EUS-controlled solar plexus neurolysis) and, 
in special cases, ablation of functional tumours causing 
clinical symptoms (*evidence level 3).
3.3. Systemic therapy
3.3.1. Somatostatin analogues
Introduction of SSA marked the greatest progress in the 
treatment of well-differentiated GEP NETs [182–185]. 
Basic indications for SSA therapy include:
A. Symptomatic treatment of functional GEP NETs
 — SSA are the ‘gold standard’ in the treatment of 
functional tumours; these medications reduce the 
secretion of hormones and biologically active sub-
stances, control the symptoms of the disease, and 
significantly improve the quality of life [1].
 — In long-term treatment octreotide LAR (10–30 mg 
i.m. every 4 weeks, but the lowest dose is rarely 
used), and lanreotide Autogel (60–120 mg s.c. every 
4–6 weeks, but the lowest dose is rarely used), are 
recommended. Treatment effectiveness is monitored 
primarily on the basis of clinical symptoms.
 — Therapy with long-acting SSA is the treatment 
of choice for the following syndromes: carcinoid 
syndrome, glucagonoma, VIP-oma (symptomatic 
treatment in these syndromes is presented in guidelines 
for pancreatic and small intestinal NENs) [156].
*evidence level according to OCEBM [274]
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 — SSA are not first-line therapy in insulinoma (diazox-
ide is initially used to control hypoglycaemia) or 
gastrinoma (in the treatment of ulcer disease, high 
doses of PPI are used). In malignant forms of insu-
linoma and gastrinoma, using SSA as the second-line 
therapy, may be effective in reducing symptoms of 
the disease (see p. 79–110) [186].
 — Short-acting SSA (octreotide, solution for injections 
100 μg/amp) are still used if prompt control of clinical 
GEP NET symptoms is required (including carcinoid 
crisis), in the perioperative period or in certain cases 
before introducing a treatment with long-acting 
analogues, in order to assess drug tolerance (see 
NENs p. 223–236) [156].
B. Stabilisation of the disease in GEP NEN  
patients
 — In antiproliferative treatment, octreotide LAR (30 mg 
i.m. every 4 weeks), or lanreotide Autogel (120 mg 
s.c. every 4 weeks) is recommended [187].
 — Antiproliferative effects of SSA have been confirmed 
in two randomised, double-blind, placebo-controlled, 
phase three studies: PROMID and CLARINET [188, 
189].
 — PROMID involved 85 patients with well-differentiat-
ed, functional, and non-functional, metastatic midgut 
NETs. Using octreotide LAR 30 mg at 4 week intervals 
extended the mean progression-free survival, and 
after 6 months of therapy the disease was stabilised in 
approximately 67% of patients, regardless of NET hor-
monal activity. The median time to tumour progres-
sion (TTP) was assessed at 14.3 months, compared to 
six months in the control group. The most beneficial 
effect was stabilisation of the tumour growth, re-
flected in extended PFS. The response to treatment 
in functional and non-functional NETs was similar; 
however, patients who underwent resection of the 
primary lesion, and those with hepatic metastases 
mass < 10% demonstrated better responses to anti-
proliferative treatment. On the basis of the PROMID 
study, octreotide LAR (30 mg i.m. at 4 week intervals) 
was registered for the treatment of patients with 
advanced NETs originating in the midgut or with 
unknown original site [188].
 — The CLARINET study involved 204 patients with 
non-functional NETs G1 and G2 (Ki-67 < 10%). The 
primary location of the NETs was the pancreas (45%), 
midgut (36%), hindgut (7%), or unknown (13%). 
Two-year treatment with Lanreotide Autogel 120 mg 
every 4 weeks demonstrated the absence of disease 
progression or death in 65% of the treated patients, 
compared to 33% of the placebo patients. Lanreotide 
statistically significantly increased the median PFS 
(progression-free survival) vs. placebo (mean PFS 
was not achieved in the treatment group, compared 
to 18 months in the placebo group). Increased median 
PFS was observed in patients with non-functional 
NETs G1 and G2 (Ki-67 < 10%) originating in the 
midgut and pancreas, regardless of the hepatic 
metastases volume of ≤ 25% and > 25%. The ha-
zard ratio (HR) was 0.47, which means reduced risk 
of disease progression or death in 53% of patients 
treated with lanreotide. Based on the CLARINET 
study, Lanreotide Autogel (120 mg s.c. every 4 weeks) 
was registered for the treatment of non-functional 
gastro-entero-pancreatic neuroendocrine tumours 
(GEP-NET) G1, and certain G2 tumours (Ki-67 in-
dex up to 10%) of the midgut (including the small 
intestine), of the pancreas, or of unknown origin, in 
adult patients with non-surgical, locally advanced, 
or metastatic tumours [189–191].
On the basis of on this study, the Polish Network of 
Neuroendocrine Tumours experts, following the 2016 
ENETS guidelines, decided that SSA can be used in 
a stable or progressive disease or in patients with NENs 
of undetermined course.
SSA are recommended as the first-line therapy 
in midgut and pancreatic NET. Octreotide is recom-
mended for the control of midgut NET G1 with low 
hepatic tumour load, while lanreotide is recommended 
in midgut and pancreatic NET G1 and G2 (Ki-67 index 
up to 10%) irrespective of hepatic tumour load (*evi-
dence level 1) [158].
General comments on the therapy with SSA:
 — SSA are usually well-tolerated, and associated 
adverse reactions are rare. Initial adverse effects, 
such as: discomfort in the abdominal cavity, flatu-
lence or steatorrhoea, usually disappear spontane-
ously within a few weeks, or during symptomatic 
treatment (e.g. pancreatic enzyme preparations). 
Other side effects include impaired glucose toler-
ance and cholelithiasis, and occur in 20–50% of 
patients (rarely symptomatic). Therefore, if surgical 
treatment and long-term pharmacotherapy with 
long-acting SSA are planned, cholecystectomy 
should be considered [1, 12].
 — Withdrawal of SSA before planned SPECT recep-
tor examination or PET/CT is recommended for 
4 weeks in the case of long-acting products, and for 
24–48 hours in the case of short-acting products. The 
treatment with SSA should be completed before the 
planned administration of PRRT. A 5-week discon-
tinuation is recommended for long-acting products, 
and 24-hour discontinuation for short-acting forms.
*evidence level according to OCEBM [274]
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Minimal consensus statement of the treatment with 
somatostatin analogues:
Therapy with somatostatin analogues is the treatment 
of choice in patients with functional and non-functional 
GEP NENs, in disease stabilisation or progression phase, 
preferably in patients with low Ki-67 proliferation index 
(*evidence level 1).
3.3.2. Interferon alpha
Interferon alpha (INF-α) is used in similar indications 
as SSA [1]. Due to the larger number of adverse reac-
tions, it is used as second-line treatment to control the 
clinical symptoms of functional tumours. Antiprolifera-
tive INF-α therapy may be indicated for GEP NENs 
with a proliferative index lower than 2–3% [191]. Due 
to limited availability in Poland, there is no previous 
experience of using INF-α for GEP NEN management.
3.3.3. Chemotherapy
Chemotherapy (ChTh) is one of many therapeutic op-
tions in gastrointestinal NENs.
In GEP NEN patients it is primarily determined by 
the histological properties of the neoplasm (histological 
grade G, Ki-67%), its primary site, disease dynamics, and 
patient’s general condition, as well as comorbidities [1]. 
The use of chemotherapy is limited in well-developed 
neuroendocrine neoplasms, but it is the fundamental 
therapy in poorly differentiated and aggressive cancers.
Adjuvant chemotherapy
In gastrointestinal G1 and G2 neoplasms, there are no 
indications for adjuvant therapy following surgical 
treatment.
In NET G3, given the high recurrence rate af-
ter radical surgical treatment, adjuvant platin- and 
etoposide-based therapy should be considered and, in 
certain cases, also in combination with radiotherapy, 
although there is no conclusive evidence to support 
such management [5, 155].
Combined treatment may be considered in patients 
following radical resection of locally advanced NECs, 
e.g. of the oesophagus, stomach, or rectum; however, 
the decision should be made on an individual basis [5].
It should be emphasised that there is no conclusive 
evidence from controlled clinical trials supporting the 
effectiveness of adjuvant therapy in G3 neuroendocrine 
neoplasms, but merely indications from data provided 
by individual centres, on which this expert opinion is 
based (*evidence level 5).
Palliative chemotherapy
In patients with well-differentiated and moderately differ-
entiated neoplasms (NET G1 and NET G2) chemotherapy 
may be considered only as palliative management in the 
case of primary generalisation of the neoplastic disease 
(metastatic phase), impossibility of radical surgical 
treatment (locally advanced process), or non-radicality 
(following cytoreductive treatment), as well as in the 
recurrence of the disease after a radical treatment with 
a massive diffusion. The most important eligibility cri-
terion for palliative chemotherapy is the symptomatic 
character of the disease and/or its dynamics, and good 
general condition of the patient (WHO/ECOG 0-2).
Palliative systemic treatment of NETs G1 and G2 
should be considered in the following cases:
 — moderately differentiated NENs with signs of pro-
gressive disease, with large tumour mass, threaten-
ing organ sufficiency, and a relatively high prolifera-
tion index: Ki-67 > 10% (NET G2);
 — locally advanced pancreatic neuroendocrine neo-
plasms NET G2 with Ki-67 5–20% in order to enable 
resection of the lesion;
 — progressing* well- or moderately-differentiated 
neoplasms of NET G1, NET G2, before and/or after 
surgery, and if previously implemented treatment 
methods failed (biological/radioisotope/locore-
gional/targeted therapies).
(*the proposed criterion is progression according to 
the RECIST score, compared against test results over 
the last 12 months).
In the absence of clinical symptoms nor risk of organ 
insufficiency, confirmation of disease progression ac-
cording to the RECIST criteria within a maximum period 
of one year, may be a relative eligibility criterion. RECIST 
progression over more than a year is not treated as an 
independent indication for chemotherapy [1, 5, 192].
It should be emphasised that chemotherapy is 
generally moderately effective in NET G1 and NET 
G2. In each case of advanced well-differentiated/ 
/moderately-differentiated GEP NEN, before deciding 
on chemotherapy, palliative local treatment of the pri-
mary lesion and/or metastases: excision (of the primary 
lesion and/or certain resectable metastases), removal 
of metastases (thermoablation, radio frequency (RF) 
ablation, NanoKnife) and palliative local techniques 
(radioembolisation and CT-controlled brachytherapy), 
or less toxic methods of systemic management, should 
be considered (biotherapy with cold SSA, peptide ra-
dioisotope therapy with hot SSA — PRRT — targeted 
therapy). The above suggestions are based on the 
opinion of experts, on international guidelines, and 
recommendations regarding treatment of GEP NETs 
(*evidence level 4).
The effectiveness of chemotherapy on well-dif-
ferentiated or moderately-differentiated GEP NETs 
(NET G1 and NET G2) is considerably higher in the 
*evidence level according to OCEBM [274]
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neoplasms of pancreatic origin than in those from 
other sites [193].
Indirect comparison of the results of clinical stud-
ies involving patients with GEP NENs demonstrates 
a higher probability of response in patients treated 
due to pancreatic NENs (43–70% compared to 5–15% 
in GEP NENs in other locations) [195, 196]. Interpreta-
tion of the results of previous studies is difficult due to 
the heterogeneity of the groups of patients regarding 
prognostic factors and the criteria used to assess the 
response (several studies involved patients who were 
not stratified according to the level of tumour diffe-
rentiation; a high number of patients with poorly dif-
ferentiated tumours [G3] was likely included: in earlier 
analyses the radiological assessment of the response to 
chemotherapy was suboptimal from today’s objective 
response rate [ORR] perspective) [196].
Multi-drug regimens using streptozocin (STZ) and 
5-fluorouracil (5-FU) or doxorubicin (DOX) are more effec-
tive compared to monotherapy, considering the response 
and survival rates (ORR — 42.7%, median overall survival 
[OS] — 15–30 months). Currently, three-drug regimens, 
especially with the use of cisplatin, are not recommended, 
due to the high risk of complications [197–199].
The effectiveness of streptozocin-based treatment 
was confirmed in a phase III study [196] involving 69 
patients with pancreatic neuroendocrine neoplasms, 
after using the STZ + DOX regimen vs. STZ + 5-FU. The 
obtained response rate (RR) was 69% vs. 45%, respec-
tively, the mean response time was 18 vs. 14 months, 
and median overall survival (OS) was 26 vs. 18 months 
[200]. However, the use of doxorubicin is limited to 
a cumulative dose of 500 mg/m2, due to the risk of 
cardiotoxicity [156].
Currently, in the therapy of pancreatic NET G1/G2, 
most expert recommendations suggest using streptozo-
cin as the main cytostatic agent in a two-drug regimen, 
as it demonstrates optimum effectiveness/toxicity ratio. 
The most recent retrospective analysis of a German 
team, based on of 96 patients, including 79.2% with 
G2 neoplasms and 6.3% with G3 neoplasms, treated 
between 1998 and 2014, and monitored on the basis 
of CT/MR examinations, with (re-)assessment accord-
ing to the RECIST 1.0 criteria, demonstrated high ef-
ficacy of combined streptozocin + 5-fluorouracil (STZ 
500 mg/m2 + 5-FU 400 mg/m2, day 1–5, ever 5–6 weeks), 
and acceptable tolerance of the treatment. At the start 
of the treatment as many as 25% of patients did not 
show radiological signs of neoplasm progression (as 
a new diagnosis). In 44% of patients the therapy was 
a second-line or later-line treatment. However, in most 
cases (93.7%) it was first-line palliative therapy. In the 
whole group of patients, the objective response rate was 
42.7%, disease stabilisation was obtained in 40.6%, and 
time to progression was estimated at 19.4 months. In 
23% of the patients, long-term stabilisation was observed 
over 2 years. Patients with Ki-67 < 15% demonstrated 
a slightly higer (but not statistically significant) response 
rate, RR, of approx. 45%. In a small group of patients with 
Ki-67 15–40%, the response rate was lower (RR 25%). 
Adverse effects typical for this regimen were observed: 
apart from haematological toxicity, 36% of patients com-
plained of nausea/vomiting, in 23% the fatigue syndrome 
was observed, in 17% symptoms of mucositis, in 14% 
diarrhoea, in 12% paraesthesias, and 25% of patients 
demonstrated renal impairment, of whom chronic im-
pairment was stated in 4% of patients [197].
In pancreatic NENs, STZ + 5-FU is still considered 
the standard treatment, although there are no ran-
domised studies comparing STZ-based regimens with 
other therapies (radioembolisation, other chemother-
apy regimens, PRRT or targeted therapies). It is worth 
noting that STZ is not registered in Poland, and is not 
easily available at present. The treatment of pancreatic 
NENs using new regimens based on capecitabine and 
temozolomide (CAPTEM) can be considered, following 
the recommendations of the European Neuroendocrine 
Tumour Society (ENETS), as an alternative regimen, 
depending on the availability of STZ/5-FU. On the 
basis of on small, prospective and retrospective stud-
ies with the use of temozolomide in combination with 
antiangiogenics or capecitabine, the response rates 
(RR) range between 15% and 70% [195, 202, 203]. The 
value of temozolomide administered as monotherapy 
or in combination with capecitabine or antiangiogenic 
agents is still being assessed in prospective clinical 
studies. It appears that a higher objective response rate 
following the use of alkalising drugs, including temo-
zolomide in pancreatic NENs may be correlated with 
the expression of the DNA-fixing enzyme — MGMT 
(O6-methylguanine DNA methyltransferase). Deficien-
cy of this enzyme is more often observed (in approx. 50%) 
in neuroendocrine neoplasms of the pancreas than in 
neuroendocrine tumours of the small intestine [205–207]. 
However, determination of MGMT expression or 
methylation status is not currently recommended as 
a criterion for the choice of chemotherapy, due to lack 
of standardised methods of MGMT determination, and 
to lack of prospective clinical studies [156].
In patients with pancreatic NENs, after failure 
of the first-line therapy, there are several options for 
a systemic therapy available for patients in good general 
condition:
 — in the case of progression with STZ, temozolo-
mide +/– capecitabine (CAPTEM) is considered as 
second-line treatment;
*evidence level according to OCEBM [274]
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 — if CAPTEM is used as first-line treatment (if STZ is 
unavailable), after progression, chemotherapy with 
oxaliplatin + 5-FU or capecitabine.
The effectiveness of oxaliplatin-based chemotherapy 
in the available studies was from 17% to 30%, and stabi-
lisation was achieved in 50–67% of patients. However, 
the studies involved very small groups of patients, and 
require further confirmation [208].
Due to the limited number of studies and their con-
tradictory results it is difficult to assess the actual value 
of chemotherapy in patients with well-differentiated 
and moderately differentiated GEP NENs located out-
side the pancreas. In some expert recommendations 
chemotherapy is not listed as a therapeutic option in 
this indication as the objective response rates (ORR) 
are limited. Systemic chemotherapy is not recom-
mended for extrapancreatic NETs, except in the case for 
biologically aggressive tumours, after other treatment 
methods have been exhausted. If the treatment is to be 
considered, two-drug regimens are used, analogous to 
those used in pancreatic neuroendocrine neoplasms. 
In clinical practice, the regimen with doxorubicin and 
5-fluorouracil, doxorubicin, streptozocin, or decarbon-
ize is usually chosen (*evidence level 4) [208, 209], or an 
entirely oral regimen of temozolomide and capecitabine 
(CAPTEM) [211]. The effectiveness of combined oxali-
platin and 5-fluorouracil derivatives [212], or irinotecan 
and 5-fluorouracil [213] has been indicated in some reports.
Poorly differentiated neoplasms — neuroendocrine 
cancers
Chemotherapy is the basic method of palliative treatment 
in advanced, poorly differentiated NECs. Poorly differ-
entiated, aggressive GEP NECs with a high proliferation 
index constitute over 10% of all neuroendocrine neo-
plasms. Their rapid growth makes them more sensitive to 
cytotoxic treatment than well-differentiated neoplasms, 
but their prognosis is much worse. The treatment of 
choice in the case of poorly differentiated GEP NECs 
is cisplatin and etoposide-based CTH, which enables 
a response of 42–70% to be obtained in patients (includ-
ing complete response in 20–25% of patients), with 
a response time rarely longer than 10 months, and me-
dian overall survival ranging from 15 to 19 months [214, 
215]. According to the results of NORDIC NEC, cisplatin 
can be substituted by carboplatin [216] (*evidence level 3).
Currently, the significant heterogeneity of neu-
roendocrine cancers is emphasised. Some of them are 
biologically closer to small-cell neoplasms with TP53 
mutations, with a high proliferative fraction (Ki-67 
80–90%) and high chemosensitivity — they should 
be treated similarly to small-cell lung cancer (G3b). 
Some demonstrate lower chemosensitivity, a less 
dynamic and aggressive course, and are associated 
with DAXX/ATRX mutations (G3a). On the basis of 
a retrospective data analysis in the Nordic study, it is 
suggested that the two populations can be differenti-
ated on the basis of Ki-67 (cut-off point at 55%), while 
other studies indicate the significance of morphologi-
cal structure (small- vs. large-cell cancer). In patients 
with G3a neoplasms one may use less aggressive 
chemotherapy regimens may use: capecitabine + 
temozolomide (CAPTEM), oxaliplatin + capecitabine 
(CapOX/XELOX); however, this is speculation only, 
unsupported by scientific evidence (*evidence level 
5) [216–218].
In the NORDIC study, patients with Ki-67 > 
55% demonstrated a higher response rate than 
the patients with Ki-67 < 55% (ORR 42% and 
15%, respectively), but shorter survival (OS 10 and 
14 months, respectively). Analysis of the 305 patients 
in this study revealed the following adverse prognostic 
factors: low physical fitness (WHO/ECOG > 2), primary 
tumours located in the large intestine and rectum, and 
increased blood platelet count or concentration of lactic 
dehydrogenase (LDH). All those factors were associated 
with shorter overall survival (OS) [216].
Clearly, in neuroendocrine cancers, escalation of 
chemotherapy beyond the two-drug regimen is not 
justified. A third cytostatic agent (e.g. paclitaxel), tested 
only in very small series, results in better response, 
but significantly increased toxicity [219]. In clinical 
practice, it is not recommended to use other regimens 
than cisplatin/carboplatin + etoposide (e.g. cisplatin and 
irinotecan, or oxaliplatin and fluorouracil) as the first-line 
treatment, unless dictated by the toxicity profile regard 
to the patient’s comorbidities.
Data regarding second-line chemotherapy after pro-
gression on PE/CE (cisplatin + etoposide/carboplatin + 
etoposide) are limited.
Second-line therapy may be considered individu-
ally, only in patients with good function levels [155] 
(*evidence level 4).
Topotecan proved to be ineffective in the therapy 
of NECs G3 [216]. Regimens based on oxaliplatin 
(FOLFOX, XELOX), temozolomide (CAPTEM), [218] or 
irinotecan (FOLFIRI, IP) are recommended [220–223], 
as they enable 23–40% response rates to be achieved 
(*evidence level 4).
In the case of good response to first-line chemothera-
py, maintained for at least 3 months after completion of 
the treatment, and without therapy-related toxicity (e.g. 
neurotoxicity, ototoxicity, or renal failure), reinduction 
with platin derivatives following the PE/CE regimen 
(cisplatin + etoposide/carboplatin + etoposide) may 
be considered.
*evidence level according to OCEBM [274]
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In the case of pancreatic and gastrointestinal NET 
G3 and NEC (well- and moderately differentiated 
tumours with Ki-67 > 20% to 55%, which are to be 
specifically identified according to the new 2017 AJCC/ 
/UICC classification), the preferred treatment method 
is chemotherapy with temozolomide and capecitabine 
(CAPTEM). Other drugs used in the treatment of these 
cases include taxanes [224].
Minimal consensus statement of the systemic chemo-
therapy:
 — In patients with NET G1 and G2 chemotherapy may be 
considered only in advanced stages. It depends on the 
histological characteristics of the NET (level of neoplasm 
differentiation), its primary location, dynamics (with 
a significant disease progression within ≤ 6–12 months), 
the patient’s general condition (WHO/ECOG 0–2), and 
comorbidities. The main eligibility criterion for chemo-
therapy is the symptomatic character of the disease or 
very dynamic progression, especially in NET G2 or NENs 
without SSTR expression.
 —  Advanced NET G1/2 of the pancreas requires individu-
alised treatment, depending on the proliferation fraction 
and symptoms of the disease. Chemotherapy is not the 
basic first-line treatment. In patients with Ki-67 < 10% 
it may be considered in the case of progression on SSA 
treatment [*evidence level 2b], or following failure of 
targeted therapy — everolimus or sunitinib [*evidence 
level 1b]). If the disease threatens organ sufficiency, or 
if it is pronounced, symptoms difficult to control oc-
cur, a two-drug regimen, optimally streptozocin-based 
regimen is recommended (*evidence level 2b). Cur-
rently, since streptozocin is not unavailable in Poland, 
temozolomide- and capecitabine-based (CAPTEM) may 
be considered.
 — In small intestinal NETs, chemotherapy is not recom-
mended in most cases (*evidence level 3). In this situ-
ation, as well as in neoplasms located in other parts of 
the gastrointestinal tract or with unknown site of origin, 
chemotherapy may be considered after exhausting all other 
therapeutic, to be used to alleviate the symptoms.
 — The basic first-line treatment of NECs is cisplatin and 
etoposide-based chemotherapy (*evidence level 3), espe-
cially in the case of NECs with a high proliferation index 
of Ki-67 > 55%. In the case of NETs G3 and NECs 
(Ki 67 < 55%) – STZ +/– 5-Fu +/– ADM may be con-
sidered, or alternatively, capecitabine and temozolomide 
(CAPTEM).
3.3.4. Targeted therapy
Molecular targeted therapies
In patients with gastrointestinal NETs, molecular tar-
geted therapy was found to be effective and safe. The 
mechanism of action of targeted medications consists in 
blocking the function of numerous receptors related to 
neoangiogenesis and neoplastic cell proliferation, and 
in inhibiting metastases. The effectiveness of targeted 
therapies was confirmed for the first time in pancreatic 
NET G1/G2 (PNET) where, at an advanced stage of 
the disease, two drugs demonstrating antiangiogenic 
properties were used: 
 — everolimus, selective m-TOR (mammalian target of 
rapamycin) pathway inhibitor, and 
 — sunitinib, RTKs (receptor tyrosine kinases) inhibitor 
[224–226]. In Poland and other EU countries, both 
medications were registered for the treatment of 
non-surgical and/or metastatic well- or moderate-
ly-differentiated neuroendocrine tumours of the 
pancreas in adult patients with progressive dis-
ease [228, 229]. Their therapeutic role is discussed 
in recommendations on pancreatic NENs (see 
p. 169–197).
On the basis of the RADIANT-4 trial, everolimus was 
registered in the US and in Europe, for treatment of 
advanced non-functional NET G1/G2 originating in the 
parts of gastrointestinal tract other than the pancreas, 
and in the lungs. This prospective, placebo-controlled, 
randomised phase III study involved 302 patients, 
of whom 24% were patients with small intestinal 
neoplasms, 13% were patients with rectal NENs, and 
approx. 30% were patients with NENs of the lungs. 
Also studied was a group of patients with unknown 
primary tumour site. A significant prolongation of 
progression-free survival was observed in the everoli-
mus group, compared to the placebo group (11 vs. 3.9 
months), with an over two-fold reduction in the risk 
of progression or death (HR, 0.48; 95% CI, 0.35–0.67; 
p < 0.00001). In most patients, disease stabilisation was 
observed (81% in the everolimus group, compared to 
64% in the placebo group), while objective responses 
were sporadic [230]. Currently (December 2016), 
everolimus therapy for extrapancreatic tumour sites 
is not refundable in Poland.
Targeted drugs, everolimus or sunitinib, may be 
considered as first-line or second-line therapeutic 
options after chemotherapy, “cold” SSA treatment 
or “hot” SSA treatment — PRRT in locally ad-
vanced, non-surgical or metastatic, well-differentiated 
(G1 and G2) gastrointestinal NETs. In compliance 
with the consensus, targeted therapies should 
not be widely used as first-line treatment, due to 
the potential risk of complications, and lack of reliable 
study results [158]. Moreover, there is no evidence to de-
termine the precise order of various therapeutic options 
in the management of NENs [231]. In the case of sequen-
tial therapy, its potential toxicity should be considered, 
as indicated by an Italian retrospective, multi-centre 
*evidence level according to OCEBM [274]
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study involving 169 patients [232]. This study revealed 
a significant increase in toxicity in patients who received 
everolimus, and were previously treated with PRRT 
and/or chemotherapy. The results of a smaller Dutch 
retrospective study involving 24 patients indicated 
that previous use of PRRT does not affect the safety 
of everolimus therapy [233]. A currently conducted 
prospective study (SEQTOR) addresses the antipro-
liferative effect of everolimus, compared to the combi-
nation of STZ/5-FU in advanced pancreatic NENs, in 
a cross-over system where therapies are switched upon 
progression (www.clinicaltrials.gov).
Understanding the side effects of treatments 
and the profile of patient’s comorbidities helps in 
deciding targeted therapy between everolimus or 
sunitinib.
According to CTCAE (Common Terminology Cri-
teria for Adverse Events v 3.0 — CTCAE) [234], the 
basic first and second degree adverse events asso ciated 
with everolimus include: mucosal lesions (64%), rash 
(49%), diarrhoea (34%), fatigue syndrome (31%) and 
infections (23%), while third- and fourth-degree AEs 
include: anaemia (6%) and hyperglycaemia (5%). 
During the sunitinib therapy first- and second-degree 
CTCAE complications included: diarrhoea (54%), 
nausea (45%), weakness (34%) and fatigue (32%), 
and serious third- and fourth-degree complications 
involved neutropenia (12%) and arterial hypertension 
(10%) [225, 226].
Both targeted medications are oral preparations, 
administered continuously until disease progression 
or unacceptable toxicity occur (everolimus at 10 mg/ 
/day, sunitinib at 37.5 mg/day).
Restrictions in the use of everolimus include uncon-
trolled diabetes mellitus or lung diseases (non-infectious 
pneumonia is a classic effect of rapamycin derivatives, 
including everolimus) [228], and serious cardiovascular 
diseases for sunitinib [229].
Using of targeted therapies in combination with 
SSA in the treatment of functional NETs is a stand-
ard practice according to ENETS [156]. Everolimus 
demonstrated the effectiveness in the treatment of 
insulinoma functional pancreatic tumours regarding 
control of symptoms such as hypoglycaemia [234, 235], 
as well as in control of carcinoid syndrome symptoms 
(RADIANT-2) [238]. A similar hypoglycaemic effect was 
demonstrated in individual cases of pancreatic NETs 
treated with sunitinib [238].
Combination of molecularly targeted medications 
with SSA (everolimus and octreotide) in the first-line 
therapy of non-functional NETs is justified only if soma-
tostatin receptor expression is observed. Any evidence 
for the superiority of a combined targeted drug and 
SSA therapy over the medication used in monotherapy 
is still insufficient (benefits regarding disease control 
> 90%, without effects on PFS) [239].
Using sunitinib with lanreotide or without SSA in 
the treatment of midgut NETs is currently under in-
vestigation in prospective, randomised, clinical studies 
(SUNLAND study). The results are not yet available, 
so the mentioned medications should only be used in 
clinical trials.
Currently, there is insufficient evidence to support 
the use of other targeted therapies, such as bevacizumab, 
sorafenib, pazopanib, or axitinib, in the treatment of 
gastrointestinal NENs [240–243].
At present, application of targeted therapy in the 
treatment of NECs in clinical practice is not justified, 
due to the lack of evidence from controlled, prospec-
tive clinical trials.
Molecularly targeted therapies — adjuvant treatment
There is no scientific evidence to justify the use of 
targeted therapies in adjuvant management (com-
plementary treatment after completed surgical pro-
cedure), neither in gastrointestinal NET G1/G2, nor 
in NECs or NET G3.
Minimal consensus statement on targeted therapy:
 — Targeted therapy (everolimus or sunitinib) may be consi-
dered only for palliative treatment in advanced stages, in 
well-differentiated pancreatic NET G1/G2 (*evidence level 
1b). The main qualification criterion for targeted therapy 
is progression while on SSA, PRRT, or chemotherapy 
(moderate or slow progression dynamics). The therapy is 
registered and available in Poland as part of the National 
Health Fund programme.
 — The combination of targeted therapy with SSA in the 
management of functional NETs is a standard procedure, 
implemented for its antiproliferative effect and improved 
control of hormonal disturbances, e.g. recurring hypo-
glycaemia in a metastatic insulinoma tumour (*evidence 
level 3).
 — Targeted therapy with everolimus in non-functional 
gastrointestinal NENS located outside the pancreas 
(NENs of the small intestine, large intestine, hepatic 
metastases from an unknown primary focus) may be 
considered after other therapeutic options have been 
exhausted, as a second- or third-line therapy (ineffective 
SSA treatment or progression following PRRT therapy) 
(*evidence level 1b).
 — In Poland and elsewhere in the EU, therapy in this indica-
tion is registered, but is not refundable in Poland.
 — Targeted therapy in NET G3 and NECs — Currently 
there is no evidence to support its effectiveness.
 — Targeted therapy as adjuvant (complementary) treatment 
— currently there is no justification.
*evidence level according to OCEBM [274]
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3.4. Radioisotope treatment
Patients with advanced, non-surgical NETS G1 and G2 are 
qualified for peptide receptor radionuclide therapy with 
radiolabelled somatostatin analogues (PRRT). There are 
no indications for radioisotope treatment as an adjuvant 
therapy following radical surgical management [1]. The 
role of radioisotope treatment in differentiated neoplasms 
with high mitotic index (NET G3) is not well understood, 
and requires further investigation. In radioisotope thera-
py of NETs radioisotope-labelled somatostatine analogues 
are used. In the treatment of neuroendocrine neoplasms, 
metaiodobenzylguanidine (131I-MIBG) derivatives la-
belled with 131I are currently used only sporadically [1].
3.4.1. Treatment with radioisotope-labelled  
somatostatine analogues
Previous experience in radioisotope therapy of NETs 
involved the use of DOTA-Tyr3-octreotide and DOTA- 
-Tyr3-octreotate labelled with 177Lu or 90Y isotopes, or 
their combination. Non-randomised clinical studies 
indicate that response to PRRT (complete and partial 
remission) can be achieved in approximately 8–46% 
of patients, with mean progression-free survival (PFS) 
after the treatment of 25 to 36 months [244–253]. In 
a prospective, randomised, phase III study to assess 
the effects of treatment with 177Lu-DOTATATE + 30 mg 
Octreotide LAR (patients with carcinoid syndrome 
symptoms) vs. 60 mg Octreotide LAR in midgut 
neoplasms, a 79% (95% CI 83% to 64%) reduction in 
the risk of progression of the neoplastic disease was 
found in the group of patients treated with PRRT. The 
response rate to radioisotope treatment (complete 
and partial remission) was 19% (95% CI: 11–26%). 
This study demonstrated for the first time the effect 
of PRRT on overall survival [253].
Patients with enhanced uptake of radiotracer in all 
neoplastic foci, in the case of small lesions with homo-
geneous tracer uptake, are candidates for radioisotope 
treatment. If uptake is not seen in all neoplastic foci and/ 
/or large foci of necrosis are found, the aim of the treat-
ment is palliative in the form of extended progression-
free survival, and of reduction of the neoplastic disease 
symptoms (e.g. carcinoid syndrome symptoms and other 
symptoms associated with advanced NET process). In 
individual cases, radioisotope therapy as a neoadjuvant 
treatment may be considered in order to reduce the tu-
mour mass before the planned surgical treatment [254].
Qualification for treatment with radioisotope-labelled 
somatostatin analogues
Qualified for treatment with radioisotope-labelled so-
matostatine analogues are patients with well-differen-
tiated and moderately differentiated GEP NETs, who 
demonstrate high somatostatin receptor overexpres-
sion confirmed by SRI the uptake should be at least 
comparable with that in the healthy liver, or higher. 
The best therapeutic effects are achieved if the uptake 
in the metastatic lesions is 2.2 times higher than that in 
the liver or in the PET/CT with an radiolabelled soma-
tostatine analogues SUVmax of 16.4 [255].
Exclusion criteria for PRRT treatment
1. No patient consent;
2. Pregnant patient (negative pregnancy test required);
3. Lactation;
4. Patient’s performance status (PS) 3 or 4 accord-
ing to WHO/ECOG classification, or according to 
Karnofsky classification < 60;
5. No radiotracer uptake in SRI;
6. Bone marrow insufficiency, namely:
 — Hb < 8 g/dL,
 — blood platelets < 80 × 103/μl, 
 — WBC < 2 × 103/μl)*,
 — lymphocytes < 0.5 × 103/μl,
 — neutrocytes < 1 × 103/μl;
7. Renal failure (GFR < 30 ml/min)*, BUN > 45 mg/dl, 
creatinine > 150 μmol/l;
8. Liver failure (three-fold increase in bilirubin con-
centration).
Due to the increased risk of adverse reactions, 
patients with leukopaenia < 3,000, neutropaenia 
< 1,500, thrombocytopaenia < 100,000, and creatinine 
clearance < 60 mg/ml, should be qualified individu-
ally [250, 256].
Data on the regarding effectiveness of the treatment 
in patients under 18 years of age are limited; therefore, 
treatment in this age group should always be consi-
dered on an individual basis.
Qualification tests prior to PRRT:
 — Neuroendocrine tumour confirmed by histopatho-
logical examination;
 — Positive result of SRI within 12 weeks prior to 
therapy, in order to assess the radioisotope uptake 
in the lesions;
 — Prior to first PRRT cycle, the patient should un-
dergo multiphase CT examination or, alternatively, 
dynamic MRI examination to assess the extent of 
the disease and to correlate with the somatostatin 
receptor examination;
 — GFR assessment (in non-conclusive cases, assess-
ment based on scintigraphy is recommended);
 — Laboratory tests:
 — Complete blood count with a smear,
 — Urea and creatinine, uric acid, with biochemical 
assessment of GFR,
*evidence level according to OCEBM [274]
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 — AlAT, AspAT, AP, and bilirubin (alkaline phos-
phatase to exclude cases with occult subclinical 
intra- and extrahepatic cholestasis),
 — CgA,
 — Other laboratory tests, according to the patient’s 
clinical condition.
PET/CT examination with 18FDG is recommended 
as a qualification test for PRRT, in order to assess the 
biological malignancy of the neoplastic disease, and as 
a prognostic factor [257, 258, 259].
Radioisotope treatment regimens
Treatment is usually conducted in four cycles, with 
intervals of 8–12 weeks, with the use of somatostatine 
analogues radiolabelled with 90Y, 177Lu, or 90Y/177Lu. 
Currently, due to lower nephrotoxicity, most centres 
prefer the use of 177Lu isotope the 90Y/177Lu tandem 
treatment. During radioisotope treatment, it is nece-
ssary to administer intravenously a solution of amino 
acids to radioprotect of the kidneys [260]. There is no 
conclusive evidence that treatment with octreotide/ 
/lanreotide reduces the effectiveness of radioisotope-
labelled somatostatine analogue therapy. This therapy 
should not be discontinued during the radioisotope 
treatment; however, it is best if the interval between 
administrations of a long-acting analogue is at least 
4 weeks. If the treatment with a SSA needs to be con-
tinued before PRRT, short-acting analogues are recom-
mended [260]. Data on biotherapy with SSA follow-
ing isotope treatment (in patients without carcinoid 
syndrome) are limited [261, 262]; therefore, decisions 
should be taken on an individual basis.
Adverse effects of PRRT
Adverse effects of the treatment concern mostly the 
haematopoietic system and kidneys. Possible adverse 
reactions should be monitored on every applica-
tion, using oncological criteria, optimally based on 
the CTC-AE NCI ver. 4.03 or later [263]. The risk of 
post-radiation damage to the kidneys is reduced by 
the intravenous administration of positively charged 
amino acids — L-lysine and arginine — prior to 
treatment. Patients with carcinoid syndrome, who 
may experience a carcinoid crisis during the therapy, 
require special attention. Short-acting SSA should be 
used with these patients directly before, during, and 
directly after PRRT.
Retreatment with radioisotope-labelled somatostatine 
analogues
In the case of progression after achieving a long-lasting, 
positive effect of radioisotope therapy, if other thera-
peutic methods are not available, retreatment of PRRT 
may be considered [264].
3.4.2. Treatment with 131I-MIBG
Since most of patients diagnosed with well-differen-
tiated/moderately differentiat NET qualify for treat-
ment with labelled SSA, currently the treatment with 
131I-MIBG is used very rarely. It may be considered in pa-
tients with negative results of SRI and present uptake of 
131I-MIBG in the primary tumour and/or metastases. The 
treatment is primarily palliative, to alleviate of the clini-
cal symptoms, including the carcinoid syndrome and 
other clinical symptoms associated with an advanced 
neoplastic process [264, 265]. Contraindications for this 
therapy include bone marrow suppression, according to 
the above criteria. In patients with a functional thyroid 
gland, it is necessary to block the uptake of free 131I not 
bound with the MIBG carrier (Lugol solution may be 
used) [1].
Qualification for 131I-MIBG radioisotope treatment
Basic tests performed to qualify a patient for radioiso-
tope treatment include diagnostic 131I-MIBG or 123I-MIBG 
scintigraphy. Iodine-123 isotope is preferred (but its 
availability in Poland is limited, due to high costs), 
as it enables performance of a whole-body SPECT/ 
/CT, including precise location of radiotracer uptake, 
and comparison with the visible NET foci in CT 
or MRI examinations. Complete blood count with 
a smear, liver and kidney tests with creatinine clearance 
complete the preparation for this therapy [1, 155, 267].
3.4.3. Evaluation of effects of radioisotope therapy
Evaluation of therapeutical effects should include mor-
phological examinations (e.g. CT, MR) [269] and soma-
tostatin receptor imaging (note: in order to assess the 
effectiveness of treatment, SRI must be performed using 
the same technique as the treatment qualifying test), ap-
prox. 3 months after completion of treatment, next every 
6 months for 2 years. Further follow-up depends on the 
clinical course of the disease. To assess the objective re-
sponse rate (ORR), RECIST classification is used; depend-
ing on the adopted model, RECIST v. 1.0 classification is 
still in use in NENs. The current classification is RECIST 
1.1. In assessment of the response to PRRT, the optimum 
methods and criteria are still searched for [269, 270].
3.4.4. Role of PRRT in the therapy of advanced  
neuroendocrine neoplasms
There are no conclusive data on the GEP NEN treat-
ment stage at which PRRT should be considered. 
Progression of neoplastic disease is an indication for 
*evidence level according to OCEBM [274]
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implementing cytotoxic therapy (chemotherapy/radio-
therapy/targeted therapy), but there is no agreement as 
to the most effective first-line treatment. The location of 
the primary focus, dynamics of the neoplastic process, 
and high overexpression of somatostatin receptors 
should be taken into account.
The main indication for PRRT is disease progression 
after biotherapy with SSA (*evidence level 1 in NETs of 
the small intestine); however, in the case of advanced 
disease, associated with the risk of organ insufficiency, 
radioisotope treatment as the first-line therapy can be 
considered (*evidence level 3). In other GEP NEN loca-
tions, radioisotope treatment may be considered in 
case of advanced disease, especially after progression 
is demonstrated in imaging examinations and if  high 
somatostatin receptor overexpression is shown in SRI 
(*evidence level 4) [1, 250].
Minimal consensus statement on the use of therapy 
with labelled somatostatin analogues
PRRT may be considered as first-line treatment in 
patients with diffused or non-surgical NETs, in particular 
those originating in the midgut, with high overexpression 
of somatostatin receptors in SRI, depending on the stage 
of disease.
In selected cases, treatment of patients with non-surgical 
GEP NENs may be conducted with the use of 131I-MIBG, 
after uptake of radioisotope-labelled biogenic amine analogue 
is confirmed in diagnostic examination (*evidence level 3).
3.5. Radiotherapy in neuroendocrine neoplasms
The common opinion that neuroendocrine neoplasms 
demonstrate low radiosensitivity is not supported by 
the published studies. Retrospective studies indicate 
potential benefits of teleradiotherapy as a palliative 
treatment or as complementary therapy following 
surgical management. In the past decade Stereotactic 
Ablative Body Radiotherapy (SABR) — or Stereotactic 
Body Radiotherapy (SBRT) have emerged, enabling 
delivery of high ablative radiation doses with high 
precision. SABR results in local control of 70–100%, 
comparable with surgical resection or with other ab-
lation methods. SABR can be used in non-resectable 
gastro-entero-pancreatic tumours (e.g. pancreatic or 
hepatic lesions).
Indications for radiotherapy are individual, and in 
symptomatic cases, with regard to metastatic lesions 
(osseous metastases, cerebral metastases). Radiotherapy 
may be considered as an alternative to surgical man-
agement in non-operative gastro-entero-pancreatic 
tumours (pancreas, liver, stomach). Complementary 
radiotherapy can be individually considered after R1 
resections in gastro-entero-pancreatic tumours. Small, 
retrospective studies indicate improved local control fol-
lowing complementary RT in patients who underwent 
R1 radical surgeries due to pancreatic NENs.
The application of radiotherapy in combined radical 
treatment of gastro-entero-pancreatic neuroendo-
crine cancers (of the rectum, rectal canal, stomach, 
oesophagus, and pancreas) is a separate issue. There 
is no consensus with regard to management standards 
for these indications. No studies are available to sug-
gest whether management guidelines should follow 
neuroendocrine cancers (mainly surgical treatment 
with adjuvant chemotherapy), or those related to 
managing adenocarcinoma or squamous cell carci-
noma (pre-operative or post-operative radiotherapy 
or chemotherapy, or chemotherapy instead of surgi-
cal treatment). It appears that the clinical course of 
neuroendocrine carcinomas is determined by biologi-
cal factors resulting from the histopathological type 
(small-cell cancers demonstrate highly metastatic 
characteristics), but also by the anatomical properties 
of the organs (lymph drainage and high risk of local re-
currence); therefore, any decision regarding combined 
treatment involving radiotherapy or chemotherapy 
should always be made by a multidisciplinary team 
of experienced specialists [271–273].
Minimal consensus statement on radiotherapy:
Radiotherapy as palliative or adjuvant treatment should 
be considered on an individual basis (teleradiotherapy, includ-
ing Stereotactic Ablative Body Radiotherapy — SABR, or 
Stereotactic Body Radiotherapy — SBRT):
 — in osseous or cerebral metastases,
 — as an alternative to surgical management in non-operative 
gastro-entero-pancreatic tumours (pancreas, liver, stomach),
 — as a complementary therapy following R1 resections in 
gastro-entero-pancreatic tumours.
4. Follow-up
Treatment monitoring should include clinical examina-
tions, laboratory tests (CgA) and imaging methods.
It is recommended to monitor the disease by 
imaging examinations, such as CT, MRI, USG, and 
endoscopic examinations, and of biochemical mark-
ers determination (CgA) every 6–12 months in NET 
G1-G2. Radioisotope somatostatin receptors imaging 
SRI should be performed 4–6 months after surgical 
treatment, and repeated every 6–24 months in NETs 
demonstrating somatostatin receptor expression.
Indications for SRI in further monitoring depend on 
the clinical advancement and location of the tumour; 
these are discussed in respective sections.
In patients with NECs, imaging examinations 
should be performed every 3–6 months, depending 
on the course of the disease.
*evidence level according to CEBM [274]
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